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Background: During pandemics of novel influenza and outbreaks of emerging infections, surge in
health-care demand can exceed capacity to provide normal standards of care. In such exceptional
circumstances, triage tools may aid decisions in identifying people who are most likely to benefit from
higher levels of care. Rapid research during the early phase of an outbreak should allow refinement and
validation of triage tools so that in the event of surge a valid tool is available. The overarching study aim is
to conduct a prospective near real-time analysis of structured clinical assessments of influenza-like illness
(ILI) using primary care electronic health records (EHRs) during a pandemic. This abstract summarises the
preparatory work, infrastructure development, user testing and proof-of-concept study.
Objectives: (1) In preparation for conducting rapid research in the early phase of a future outbreak, to
develop processes that allow near real-time analysis of general practitioner (GP) assessments of people
presenting with ILI, management decisions and patient outcomes. (2) As proof of concept: conduct a pilot
study evaluating the performance of the triage tools ‘Community Assessment Tools’ and ‘Pandemic
Medical Early Warning Score’ to predict hospital admission and death in patients presenting with ILI to GPs
during inter-pandemic winter seasons.
Design: Prospective near real-time analysis of structured clinical assessments and anonymised linkage to
data from EHRs. User experience was evaluated by semistructured interviews with participating GPs.
Setting: Thirty GPs in England, Wales and Scotland, participating in the Clinical Practice Research Datalink.
Participants: All people presenting with ILI.
Interventions: None.
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Main outcome measures: Study outcome is proof of concept through demonstration of data capture
and near real-time analysis. Primary patient outcomes were hospital admission within 24 hours and death
(all causes) within 30 days of GP assessment. Secondary patient outcomes included GP decision to
prescribe antibiotics and/or influenza-specific antiviral drugs and/or refer to hospital – if admitted, the
need for higher levels of care and length of hospital stay.
Data sources: Linked anonymised data from a web-based structured clinical assessment and primary
care EHRs.
Results: In the 24 months to April 2015, data from 704 adult and 159 child consultations by 30 GPs were
captured. GPs referred 11 (1.6%) adults and six (3.8%) children to hospital. There were 13 (1.8%) deaths
of adults and two (1.3%) of children. There were too few outcome events to draw any conclusions
regarding the performance of the triage tools. GP interviews showed that although there were some
difficulties with installation, the web-based data collection tool was quick and easy to use. Some GPs felt
that a minimal monetary incentive would promote participation.
Conclusions: We have developed processes that allow capture and near real-time automated analysis of
GP’s clinical assessments and management decisions of people presenting with ILI.
Future work: We will develop processes to include other EHR systems, attempt linkage to data on
influenza surveillance and maintain processes in readiness for a future outbreak.
Study registration: This study is registered as ISRCTN87130712 and UK Clinical Research
Network 12827.
Funding: The National Institute for Health Research Health Technology Assessment programme. MGS is
supported by the UK NIHR Health Protection Research Unit in Emerging and Zoonotic Infections.
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Plain English summary
Severe pandemics of influenza (flu) and other new infections are rare but inevitable events. When thesewidespread outbreaks of disease occur, health-care capacity in communities and hospitals can be
overwhelmed. Doctors then need to make difficult decisions about who should be admitted to hospital
and who can safely be allowed to stay at home.
To do this fairly, most doctors feel that the same type of patient assessment should be used across the
wider community. This process is called triage.
The ethical principle of triage is ‘to do most for most’. This does not mean treating everybody equally.
It means using scarce resources for those people most likely to benefit from treatment.
Triage tools should help doctors identify which people are most likely to benefit from treatment in hospital
and which people can safely be managed at home.
The difficulty in designing triage tools for a future pandemic is that the nature of disease caused by a new
pathogen (bacteria or virus) is unknown until that pandemic occurs. A further difficulty is that disease
often can affect children and adults quite differently. A one-size-fits-all tool is unlikely to work.
This study developed processes that capture information from general practitioner consultations of people
with flu-like illness and their electronic health record, and links this information to the hospital record if the
patient is admitted to hospital.
This means processes are ready to check that triage tools are ‘fit for purpose’ at the start of a pandemic,
for use should that pandemic become severe.
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Scientific summary
Background
During pandemics of novel influenza and outbreaks of other emerging infections, surge in health-care
demand can exceed capacity to provide normal standards of care. During surge, workload pressures may
limit the time available for clinical decision-making and health-care worker absence because of personal
sickness, or caring for dependants, may limit the skill mix. Imaging and laboratory services may also be
limited. Health-care workers who are unfamiliar with clinical assessment and admission decision-making
may be asked to fulfil ‘gatekeeper’ roles. In such exceptional circumstances, triage tools may aid decisions
in identifying people who are most likely to benefit from higher levels of care.
Provisional UK Emergency Planning Guidance published in 2007 suggested the use of the CURB-65
pneumonia score and the Pandemic Medical Early Warning Score (PMEWS) for hospital triage of adults,
but did not address the needs of children. Recognising this gap, a ‘toolkit’ of national guidance was
developed in 2008 by the Department of Health for the UK, which included the newly developed
Community Assessment Tools (CATs) for both children and adults in primary and secondary care, and
matched hospital care pathways. The validity and utility of using triage tools in the community to aid
management decisions during a pandemic remains untested. Both PMEWS and CATs were developed
specifically with this purpose in mind and so we aimed to capture the criteria that would allow validation
of these tools in this study.
The validity and utility of triage tools needs to be assessed in a large community-based prospective study of
patients presenting with influenza-like illness (ILI), to give confidence to general practitioners (GPs) who
may be asked to use such tools in the event of surge, and policy-makers who may need to recommend
their use to GPs. Validation of a triage tool for use in an outbreak of a novel disease requires rapid
research during the early phase of that outbreak. Rapid research should allow refinement and validation
of triage tools so that in the event of surge a valid tool is available.
Objectives
1. In preparation for conducting rapid research in the early phase of a future outbreak To develop
information technology (IT) infrastructure and processes that allow near real-time analysis of GP
assessments of people presenting with ILI, and GP management decisions and patient outcomes.
2. As proof of concept and to test processes To conduct a pilot study evaluating the performance of the
triage tools ‘CATs’ and ‘PMEWS’ in predicting hospital admission and death in patients presenting with
ILIs to GPs during inter-pandemic winter seasons.
3. To conduct a prospective near real-time analysis of structured clinical assessments for ILI using primary
care electronic health records (EHRs) during a pandemic.
This report addresses only the first two objectives, involving preparatory work that would make the third
objective feasible in the event of a pandemic.
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Methods
Aim
The overarching study aim is to conduct a prospective near real-time analysis of structured clinical
assessments of ILI using primary care EHRs during a pandemic. This report covers the preparatory work,
that is, IT infrastructure development, user testing and pilot study as ‘proof of concept’.
Design
The proof-of-concept study involved setting up and piloting a prospective near real-time analysis of
structured clinical assessments and anonymised linkage to data from EHRs. User (GP) experience was
evaluated by semistructured interviews. Processes were also developed for retrospective validation
of outcome events using Hospital Episode Statistics (HES) and Office for National Statistics (ONS)
mortality data.
Setting
Thirty GPs in England, Wales and Scotland participating in the Clinical Practice Research Datalink (CPRD)
using the Vision® version 3.01 (In Practice Systems Ltd, London, UK) EHR.
Participants
All people presenting with ILIs to participating GPs.
Interventions
None.
Main outcome measures
Study outcome is proof of concept through demonstration of data capture, appropriateness of data
definitions and near real-time analysis. Primary patient outcomes are hospital admission within 24 hours
and death (all causes) within 30 days of GP assessment. Secondary patient outcomes included GP decision
to prescribe antibiotics and/or influenza-specific antivirals and/or refer to hospital, need for higher levels
of care if admitted, and length of hospital stay.
Data sources
Linked anonymised data from a study-specific web-based structured clinical assessment and primary care
patient EHRs. Retrospective validation of hospital admission was planned using HES, and mortality data
validation was planned using ONS data.
Results
In the 24 months prior to April 2015, data from 704 adult and 159 child consultations to 30 GPs were
captured. Influenza activity during these two winter seasons was low. GPs decided to refer 11 (1.6%)
adults and 6 (3.8%) children to hospital. There were 13 (1.8%) deaths among adults and 2 (1.3%)
among children. There were too few outcome events from which to draw any conclusions regarding the
performance of the triage tools; however, the data captured allowed testing of almost all analytical
algorithms and demonstrated proof of concept.
Data relating to each GP consultation were uploaded on to the CPRD database every night. The CPRD
team then collated these data and sent weekly data to researchers based at the Universities of Nottingham
and Liverpool. Additionally, on a monthly basis, the CPRD team sent background data (comorbidities,
prescriptions, death, etc.) sourced from the EHRs for all patients with captured consultations. Each
subsequent data instalment comprised the cumulative data acquired since the initiation of the study.
Validation of outcome events with HES and ONS data was not possible for inclusion in this interim report
because of a moratorium on provision of this data by the Health and Social Care Information Centre.
SCIENTIFIC SUMMARY
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Six participating GPs agreed to be interviewed about their user experience. The main finding that emerged
from these interviews was that the Local Eligibility Patient Identification Software (LEPIS) and web-based
electronic Case Report Forms (eCRFs) were easy to use. The simplicity of the eCRFs encouraged GPs to
participate in the study despite there not being any financial incentive for participation.
The GPs reported that the triage process of the consultation was quite easy to conduct and did not
interfere with the routine GP consultation. Several GPs felt that a monetary incentive, even if small, would
be necessary to increase GP participation in the study unless there was a statutory requirement to
systematically collect data on all possible influenza cases during a pandemic. All interviewed GPs agreed
that the FLU-CATs eCRF, with a few modifications, was ready to be used in a pandemic scenario.
However, the setting up of the LEPIS system to enable data collection for the study was fraught with
technical difficulties and not compatible with other EHR systems in use in the UK. Both these points are
important limitations that would prevent a rapid national level rollout beyond the 650 plus practices
currently using the Vision® EHR platform. Any decision aid based on the validated criteria could better be
delivered separately on an open web-based platform or mobile phone ‘app’.
Lessons learnt from the data analysis included that up to 74% of some clinical measurements (blood
pressure in adults in this instance) were not recorded as part of GP’s routine assessment of an adult person
presenting with ILI. We would question the utility and adoption of triage tools that depend upon a clinical
measurement that is not used in the routine assessment of ILI for use in a time-pressured pandemic situation.
Conclusions
The use of EHRs linked to study-specific data capture forms increased the comprehensiveness, validity and
usability of data; pre-prepared analytical processes allowed near real-time analysis of GP assessments,
management decisions and patient outcomes on a weekly basis. The processes are dynamic and should
allow refinement of triage criteria in the early stages of a future outbreak.
Future work
We will test the effect of minimal remuneration on recruitment in future seasons, develop processes to
include other EHR systems, attempt linkage to data on influenza surveillance and maintain processes in
readiness for a future outbreak.
Study registration
This study is registered as ISRCTN87130712 and UK Clinical Research Network 12827.
Funding
The National Institute for Health Research Health Technology Assessment programme. MGS is supported
by the UK NIHR Health Protection Research Unit in Emerging and Zoonotic Infections.
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Chapter 1 Introduction
A surge in health-care demand can exceed capacity to provide normal standards of care duringpandemics of severe influenza and other emerging infections. Surge is recognised in historic reports
of influenza pandemics and current government guidance.1,2 In such exceptional circumstances triage tools
may aid decisions in identifying people who are most likely to benefit from higher levels of care. Triage
tools have value only if they can reliably identify individuals who benefit from higher levels of care, thus
maximising outcome for a limited health-care resource and allowing other essential health-care activity to
continue. Practitioners and policy-makers require confidence in the evidence behind triage criteria, and
reassurance that a triage tool is valid for use in a particular situation. However, it is, by definition,
impossible to establish the relationships between the presenting clinical characteristics and outcome for
a novel pathogen causing disease in a heterogeneous population of varying age and comorbidities without
conducting rapid research during the early phase of that outbreak. Validation of a triage tool for use in a
novel disease requires rapid research during the early phase of that outbreak. Rapid research should allow
refinement and validation of triage tools so that in the event of surge a valid tool is available.
In 2009, during the early phase of the A/H1N1pdm2009 pandemic, health-seeking behaviour due to
perceived risk of influenza increased quite out of proportion to influenza-like illness (ILI) activity in the
community.3 This placed exceptional pressure on primary health-care services and interfered with capacity
to deliver both routine and emergency care to previously accepted standards. In England, the National
Pandemic Flu Service, which relied upon clinical algorithms, was introduced in mid-July 2009 in order to
relieve pressure on primary care services.4 Later in the same outbreak, ILI in some regions exceeded the
capacity of secondary care to continue some routine and specialist services.
In either situation, workload pressures may limit the time available for clinical decision-making, and
health-care worker absence due to personal sickness or caring for dependants may limit the skill mix.
Access to imaging and laboratory services may also be restricted. Health-care workers who are unfamiliar
with clinical assessment and admission decision-making may be asked to fulfil ‘gatekeeper’ roles.5
Together, these factors place increased reliance and emphasis on core clinical history-taking and
examination skills for triage decisions, which may be devolved to less-experienced staff.
Triage tools for influenza
Provisional guidance6 suggested the use of the CURB-65 pneumonia score7 and the Pandemic Medical
Early Warning Score (PMEWS)8 for hospital triage of adults in the UK. Importantly, neither score was ever
intended for use in children. Most children can benefit from access to adult critical care facilities and
general intensive care units when there is no paediatric intensive care unit capacity. Recognising this gap,
a ‘toolkit’ of national guidance was developed in 2008 in the UK, which included newly developed
Community Assessment Tools (CATs) for both children and adults in primary and secondary care, and
matched hospital care pathways.2 None of the recommended triage tools was validated in the context of
a novel influenza outbreak at the onset of the A/H1N1pdm2009 outbreak.
CURB-65
‘CURB-65’ is a validated predictor of mortality from community-acquired pneumonia in adults but
it was never intended for use in children.7,9 CURB-65 was not designed to predict mortality from
non-pneumonic presentations.8–10
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Pandemic Medical Early Warning Score
Challen et al.11 proposed the PMEWS as a clinical triage tool to aid hospital admission decisions for
adults in a pandemic situation. The PMEWS score attributes an ordinal value to ranges of physiological
measurements (respiratory rate, oxygen saturation, heart rate, systolic blood pressure, temperature and
neurological assessment) and patient characteristics (age, social factors, chronic disease and performance
status) to generate a score of between 0 and 20 (Table 1). They validated PMEWS in adults presenting to
hospital with community-acquired pneumonia and found that it was better than CURB-65 for predicting the
need for admission and higher levels of care, but had limited ability to predict mortality. CURB-65 and
PMEWS pose problems for use in primary care: CURB-65 is reliant on a contemporaneous serum urea value,
PMEWS could be computationally complicated for some, and both are designed for use only with adults.
Many people presenting with ILI are children. Other severity scoring tools exist but these are not suitable for
use in primary care because of a greater dependence upon laboratory or radiological investigations.
TABLE 1 Pandemic Modified Early Warning Score (reproduced with author’s permission)
Ring 1 value for each factor
Physiological
measurement
Score
3 2 1 0 1 2 3
Respiratory rate (breaths
per minute)
≤ 8 9–18 19–25 26–29 ≥ 30
Oxygen saturation (%) < 89 90–93 94–96 > 96
Heart rate (beats
per minute)
≤ 40 41–50 51–100 101–110 111–129 ≥ 130
Systolic blood pressure ≤ 70 71–90 91–100 > 100
Temperature (°C) ≤ 35.0 35.1–36 36.1–37.9 38–38.9 ≥ 39
Neurological assessment Alert Confused, agitated Voice Pain, unconscious
PLUS
Score 1 for each factor
l Age > 65 years
l Social isolation or living alone/no fixed abode
l Chronic disease or respiratory, cardiac, renal, immunosuppressed, diabetes mellitus
l Performance statusa > 2
Total P MEWS =
a Assessing performance status: normal activity without restriction, 1; strenuous activity limited, can do light, 2; limited
activity but capable of self-care, 3; limited activity, limited self-care, 4; confined to bed/chair, no self-care, 5.
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Department of Health Community Assessment Tools
In 2009, the Department of Health in England published a package of care that included paediatric and
adult CATs and patient pathways for use by the national health services of the UK nations in a severe
pandemic event, in primary and secondary care, and matched hospital care pathways.12 CATs were
developed to help non-specialist front-line staff identify, when resources are limited, which sick children and
adults are most likely to benefit from interventions and levels of care that are available only in hospitals.
CATs were developed by paediatric and adult expert clinical development groups drawing on evidence that
supports the recognition of severe influenza and severe pneumonia in the community in adults and children
in resource-limited settings, severe chronic obstructive pulmonary disease in adults, potentially serious
feverish illness in children and severe bronchiolitis in infants.5,13–22 Clinicians were warned not to use the
CATs and the pathways unless the local situation precluded normal admission and discharge processes.
Community Assessment Tools use six objective criteria and one subjective criterion based on simple (binary)
clinical assessment (Figures 1 and 2). Meeting any CATs criterion warrants referral and admission to
hospital. Criteria are (1) severe respiratory distress; (2) increased respiratory rate; (3) oxygen saturation
of ≤ 92% on pulse oximetry breathing air or oxygen; (4) respiratory exhaustion; (5) severe dehydration or
shock; (6) altered consciousness level; and (7) other clinical concern. Although criteria fields are common to
paediatric and adult CATs, the abnormal physiological thresholds and clinical signs are age appropriate.
Like PMEWS, there is no requirement for laboratory investigation to complete the assessment. However,
CATs was intended for use only ‘during severe and exceptional circumstances when surge demand for
health-care services leads to a need for strict triage’12 and, as such, was not deployed during the
2009–10 pandemic.
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FIGURE 1 Paediatric Community Assessment Tool for children aged < 16 years. © Crown Copyright, Department of
Health, 2009, reproduced under Open Government Licence for public sector information.
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FIGURE 2 Adult Community Assessment Tool for adults aged ≥ 16 years. © Crown Copyright, Department of Health,
2009, reproduced under Open Government Licence for public sector information.
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Work underpinning this study
Goodacre et al.23 conducted an evaluation of the discriminatory value of the CURB-65 score, PMEWS and
CATs for predicting severe illness or mortality in 481 patients (346 aged < 16 years) presenting to hospital
with suspected pandemic influenza. Initially they were unable to draw any conclusions regarding their
clinical utility in a pandemic situation because of insufficient numbers of adults and a low incidence of
severe outcome. In a later analysis of the same data, sensitivity, specificity and area under receiver
operating characteristic (AUROC) values were reported for adults using these three triage tools with
caveats regarding the power of the study.24
In another study, PMEWS scores were calculated from a retrospective data enquiry of 300 adult patients
with suspected pandemic influenza, who were assessed in the community by Ambulance Service
emergency-care practitioners. AUROC curves suggest that PMEWS scores discriminate between decision to
‘treat and leave’ and ‘transfer for hospital assessment’.25
The UK Pandemic Influenza Clinical Information Network (FLU-CIN) characterised polymerase chain
reaction-confirmed pandemic influenza disease in a cohort of 1520 people [1040 adults, 480 children
(aged < 16 years)] admitted to hospital.26 FLU-CIN compared the clinical validity and utility of CATs,
PMEWS and CURB-65 as predictors for interventions that are normally available only in hospital, higher
levels of care and death using AUROC curve comparisons with 95% confidence intervals (CIs).27 CATs
showed the best predictive performance for level 2/3 admissions in both adults [AUROC: CATs 0.77 (95% CI
0.73 to 0.80); CURB-65 0.68 (95% CI 0.64 to 0.72); PMEWS 0.68 (95% CI 0.64 to 0.73), comparison of
AUROCs; p< 0.001] and children [AUROC: CATs 0.74 (95% CI 0.68 to 0.80); CURB-65 0.52 (95% CI
0.46 to 0.59); PMEWS 0.69 (95% CI 0.62 to 0.75); p< 0.001].
Although the FLU-CIN cohort is limited to patients admitted to hospital with severe influenza and its
complications, the data show that these triage tools are capable of predicting higher levels or care and/or death
in children and adults. However, the FLU-CIN analysis did not include assessment of triage tools in primary care.
Appropriate use of such triage tools in the community could expedite referral to hospital and, when scores
are high, immediate admission to level 2/3 care. Prompt admission and allocation of higher levels of care
may be associated with improved patient outcomes. Another study26 by FLU-CIN found that delayed
admission to hospital (≥ 4 days after symptom onset) was significantly associated with increased likelihood
of admission to critical care and death.
Morbidity and mortality rates were low during the influenza A/H1N1pdm2009 pandemic compared with
some previous influenza epidemics, such as that in 1989–90.28 The use of antiviral therapy was generally
low in the FLU-CIN cohort despite it being widely available at the time. A more severe pandemic may be
associated with a greater acceptance of antiviral therapy, and this may impact upon need for higher levels
of care and death. Consequently, criteria threshold values may need to be adjusted to optimise the receiver
operating characteristic curve for each criterion and the AUROC curve for the various triage tools.
The validity and utility of using triage tools in the community to aid management decisions during a
pandemic remains untested. Both PMEWS and CATs were developed with this purpose in mind and so we
aimed to capture the criteria that would allow validation of these tools in this study.
INTRODUCTION
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Justification of this study
The validity and utility of triage tools need to be assessed, in a large community-based prospective study of
patients presenting with ILI, to give confidence to general practitioner (GPs), who may be asked to use
such tools in the event of surge, and policy-makers who may need to recommend their use to GPs. The
routine use of electronic health records (EHRs) by GPs and existing permissions to access anonymous data
for research purposes presents an opportunity to study GP assessments, management decisions and
patient outcomes. Anonymous linkage of this GP-derived data to Hospital Episode Statistics (HES) data for
hospital admissions and Office for National Statistics (ONS) data for causes of death permits a validation
of the GP-derived data. Together, these processes should allow for the assessment and comparison of the
validity and utility of triage tools in the community in relation to patient relevant outcomes (hospital
admission, length of stay, higher levels of care and death).
The Health Protection Agency timeline for the UK 2009 pandemic showed only 12 weeks between
identification of person-to-person transmission in the UK (first week of May) and peak influenza activity
(last week of July) in the first pandemic wave. Prospective data collection with near real-time iterative and
cumulative analysis is the only method for validating triage criteria and tools against a novel pathogen in
such a short time.
As pandemics are unpredictable and infrequent, limited but potentially useful information will be gained
from prospective feasibility and pilot work conducted in primary care during seasonal influenza while
A/H1N1pdm2009 is still circulating. It would not be possible to conduct such a study properly during a
pandemic without prior permissions, preparation of processes, feasibility and testing performance with
a pilot. The UK National Institute for Health Research (NIHR) recognised the need to fund and support the
rapid set-up of relevant research studies and ensure that these studies are successfully conducted so that
their findings can inform the ongoing care of patients during an outbreak. This will require some changes
to the usual processes undertaken by the Clinical Research Network, as well as the reprioritisation of
both national and local resources in what may well be a challenging environment in terms of increased
demands for patient care and falling staff numbers because of illness. Consequently, the Clinical Research
Network has an urgent public health plan in place to ensure that urgent public health studies can be set
up and delivered quickly and effectively. The Clinical Research Network’s urgent public health risk process
will be activated at the request of the Department of Health. The FLU-CATs Study is one of the portfolio of
studies that have been identified and granted the relevant research approvals in advance of an outbreak.29
Conducting this study in real-time during the early stages of a pandemic, when the characteristics of the
novel virus are not fully understood, is important as it allows refinement and validation of triage tools
against the novel pathogen in preparation for possible surge. This cannot be done until a novel virus
emerges. Dame Deirdre Hine has recommended that population-based studies be established that,
in the early stages of a future pandemic, can measure the severity of the pandemic and support
decision-making.30
If the behaviour of the virus is markedly different in terms of severity between the first and subsequent
waves, or evolves to cause severe disease in a particular organ system (as happened in the 1918–19
pandemic) then triage criteria may need to be adapted to reflect the consequent changes in health-care
demand and clinical presentation.
The objective of this study was to establish processes now, in advance of a future pandemic, to validate
the community triage tools capable of assisting hospital referral decisions for people of all ages for use
if health-care demands exceeded health-care capacity (surge).
The development of a triage tool has three distinct phases (set-up, pilot and implementation). It is
expected that a triage tool would be implemented only in the exceptional circumstance of surge during an
influenza pandemic or substantial outbreak of a novel emerging respiratory pathogen of public health
interest. This study reports the set-up and pilot phases of this plan of work.
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Chapter 2 Methods
The study was conducted in primary care settings in the UK. These are community settings in whichmedical care is provided by GPs. The study was restricted to those GPs whose practices participate in
the Clinical Practice Research Datalink (CPRD).
The study is made possible by consistent routine use by GPs of EHRs, an autonomous software agent that
sits beside that system, and anonymised patient-specific linkage to external data sources. Figure 3 outlines
the source and flow of information. In principle, any of the electronic patient management systems in use
could be used. We chose the Vision® version 3.01 (In Practice Systems Ltd, London, UK) platform because
of the established linkage with CPRD. CPRD is the governmental centre, jointly funded by NIHR and the
Medicines and Healthcare products Regulatory Agency (MHRA), which aims to provide anonymised
health-care records for data services, interventional and observational research.31 CPRD has ethical and
regulatory approval to use anonymised patient data collected in over 650 participating GP practices and for
linked–anonymised data access to individual patient data in the NHS England HES and mortality data in
the ONS data set for approved purposes.
Eligible patients for the study were identified using Local Eligibility Patient Identification Software (LEPIS).
LEPIS was developed for use with the electronic patient records software Vision® by researchers at Kings
College London. LEPIS is an autonomous software agent that sits in the software background during a
GP–patient consultation. It is remotely programmable by secure Ethernet to identify eligible patients using
any combination of demographic features, Read codes and medications. LEPIS silently monitors the GP’s
data entry for all consultations. When an eligible patient is identified, a pop-up window appears on
the screen offering the opportunity to recruit that patient into a study. If recruited, LEPIS then ‘pipes’ the
patient data to study specific processes. Further details of LEPIS are provided elsewhere.32
FIGURE 3 Architecture of the real-time surveillance system.
DOI: 10.3310/hta19890 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 89
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Venkatesan et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
9
Phase 1: set-up of the study, development of the technology
and feasibility
This phase involved development of systems and feasibility testing. The information technology (IT) solution
was deployed over 6 months between March and September 2013: in the UK this is not an endemic
influenza season, and it occurred during an inter-pandemic period. Processes included set-up and
validation of processes; optimisation of the clinical record entry screen; GP acceptability testing;
establishing data-return format; check completeness of data returns; develop data clean-up algorithms;
development of definitions, evaluation of completeness and validation of study outcomes using
retrospective CPRD, HES and ONS data; and testing of LEPIS.
Developing the real-time surveillance system
Eligible patients for the study were identified during GP consultations using LEPIS loaded on participating
GPs’ computers. LEPIS monitors the consultation record for entry of any eligible diagnostic Read code
(see Appendix 1). When a participating GP enters a relevant diagnostic Read code, a pop-up window
appears prompting them to consider recruiting the patient; not recruiting; or suspending further
recruitment prompts for a period of time (Figure 4). If recruited, a form appears for structured entry of data
related to the consultation (i.e. signs and symptoms, physiological measurements and decisions relating
to treatment or hospital referral). The linkage between the LEPIS and Vision® systems enabled automatic
triggering of tailor-made data entry forms based on age and sex for men, women and children
(age < 16 years), with additional conditional questions relating to pregnancy status if female and
age > 12 years. These forms are the electronic case report forms (eCRFs) for the study. The eCRFs were
designed to encourage both positive and negative reporting. The eCRFs underwent revision after the first
winter season to record if the GP actively decided not to make an assessment because the GP considered
the feature to be grossly normal or abnormal. This important feature avoids bias in the analysis of data
that might otherwise be considered missing at random, when, in reality, the data are missing because the
FIGURE 4 Screenshot of LEPIS pop-up window indicating an eligible patient.
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GP considered the feature to be grossly normal or abnormal. This addresses one challenge of collecting
data from routine consultation records, when many clinicians record only a limited number of important
negative or positive features based on their personal practice.
Age- and gender-specific eCRFs were developed. Patients aged < 16 years are classified as ‘children’ and
patients aged ≥ 16 years are classified as ‘adults’. Data collection forms for female patients > 12 years
include a query on pregnancy status. A screenshot of a sample female adult LEPIS form is provided
(Figure 5). The data collection form for children is identical to that for adults, except for three questions
that are absent in the children’s form – blood pressure measurement, social isolation status and premorbid
performance status – as these criteria are used only in the adult PMEWS triage tool.
Sociodemographic and relevant medical history data were extracted by a background process from the
routine EHR to minimise GP workload.
The flagging system and web-based data collection form was user-tested by GPs at five practices. Sample
web-based forms can be viewed at www.cprd.com/flucats/ (accessed 5 August 2015); these will be
maintained for the duration of the study.
FIGURE 5 Sample data collection form for adult female. (continued )
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FIGURE 5 Sample data collection form for adult female. (continued )
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FIGURE 5 Sample data collection form for adult female.
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Data entry checks were incorporated in the eCRF so that measurement values could be entered only if
they were within physiologically plausible ranges. To further minimise duplication of tasks, after the
completion of each form, GPs are presented with a summary of their assessment along with any decisions
made (to treat with antivirals and/or antibiotics, and referral to hospital). This can be cut and pasted, or
downloaded in text or portable document format (PDF) for entry into the patient’s EHR. A screenshot of a
sample GP summary generated following the submission of the data collection form is shown in Figure 6.
Eligibility criteria
All people (any age, any sex) presenting with ILI (regardless of date at onset of disease and prior medical
history) to GPs participating in CPRD are eligible for this study. The challenge was to identify a set of Read
codes that LEPIS would monitor and pop up to prompt GPs to recruit people with ILI, while not
overburdening the GPs with irrelevant prompts.
FIGURE 6 Sample GP summary screen.
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Eligible Read codes were identified by systematic analysis of the CPRD database using a ‘reverse
engineering’ process. First, we identified patients of any age admitted to hospital in the winter of
2010–11, who had a diagnosis of ‘influenza’, ‘an influenza-related condition’ or ‘complication of influenza’
in the HES data set, and extracted their CPRD/HES linked data. To identify these patients, we searched for
terms such as ‘influenza’, ‘influenza-like illness’ and ‘acute respiratory infection’ (see Appendix 1 for initial
list of eligible Read codes) in the Read-coded clinical terms dictionary. Next, the output was restricted to
patients who had visited their GP in the 7 days prior to admission. Then we queried the CPRD data to list
all Read codes used by GPs in these consultations that preceded the hospital admission. A total of 831
different Read codes were recorded for these GP consultations. Many of these consultations were
unrelated to ILI. These Read codes were reviewed for relevance by PM and MGS, without sight of their
frequency, to yield a shortlist of 39 codes. These codes were then listed by frequency and reviewed by the
study steering group (see Appendix 2). We decided to use all of these codes at least initially as a previous
consultation with GPs suggested that GPs prefer syndromic codes for ILI to reflect the diagnostic
uncertainty in the absence of laboratory confirmation of influenza. It is our intention to refine the LEPIS
trigger list at an interim analysis during the final phase of the study, that is, during a pandemic.33
Recruitment of general practitioners
General practitioners from practices that were already contributing to the CPRD were invited to participate
in the study by the CPRD team initially by post and followed up electronically. Further recruitment of CPRD
GPs was conducted via the NIHR Primary Care Research Networks (PCRNs), and by CPRD and investigator
activities at regional and national meetings of GP research groups. GP practices were required to install
the LEPIS software on their practice computer system and were given remote IT support. GPs were briefed
on the eligible Read codes so that they had the option of proactively triggering the LEPIS pop-up window.
No monetary incentives were provided to GPs for participation in the study. Following correspondence
with the Royal College of General Practitioners (RCGP), they were sent certificates to include in their
continuing professional development portfolios.
Data linkages, validation of primary outcome measures, influenza
surveillance data and expansion of study to other electronic health
record systems
The study protocol included plans to validate the primary and secondary outcome events using HES data
for ‘hospital admission within 24 hours of the consultation’ and ONS data for the outcome ‘death
(all causes) within 30 days of the consultation’. In addition, at the request of NIHR reviewers, the feasibility
study scope was expanded to explore linkages with Public Health England (PHE) data sets for data on
microbiology and virology. The feasibility study also explored options for expansion of the study-specific
technological infrastructure to all CPRD and non-CPRD GP practices in the event of a pandemic.
Automation of data extraction, analysis and reporting
Algorithms or ‘do files’ were developed and tested using Stata version 13 (StataCorp LP, College Station,
TX, USA) to automate data linkage, extraction, analysis tasks and reporting to facilitate timely production
of weekly and monthly reports on the incidence, progression and outcomes of pandemic influenza or a
similar pandemic caused by a respiratory virus manifesting as ILI (see Appendix 3 for ‘do files’).
Evaluating user experience
Feedback on the ease of use of the study flagging and data collection system was obtained from
participating GPs via e-mail consultation and one-to-one telephone interviews. Interviewees were provided
a financial incentive for participation. A semistructured interview guide was used for the telephone
interviews (see Appendix 4). Interviews were audio-recorded and transcribed verbatim for thematic
analysis. Data were analysed using a thematic analysis approach that enables the researcher to identify,
analyse and report themes or patterns in the data collected. The analysis followed the steps outlined by
Braun and Clarke,34 beginning with familiarisation of the data through listening to the recording of the
interviews, transcribing the data then reading and re-reading each interview, making initial codes in
the margins.
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Coding was conducted systematically, taking each interview initially in turn and then subsequently moving
back and forth across the data set. In order to establish consistency in coding, and thereby enhance
dependability and credibility, the transcripts were independently double-coded by two of the authors
(SV and PRM). Initial themes were reviewed and refined further, and a revised thematic table of candidate
themes was produced.
Phase 2: pilot study, data collection, extraction and
statistical analysis
This phase involved data collection, extraction and statistical analysis from cases of ILI presenting to GPs.
This pilot phase has run over two consecutive winter periods: 2013–14 and 2014–15 during an
inter-pandemic period. We developed an automated weekly statistical evaluation of performance of triage
criteria and tools. This phase is expected to continue to run in subsequent winter periods in a small
number of practices as a maintenance process to ensure viability of processes as core systems continue to
evolve and as EHR systems change.
Aim
To investigate the predictive performance of the triage tools CATs and the PMEWS for hospital admission
and death in patients presenting with ILI to primary care, using a novel near real-time data collection,
collation, linkage and analysis process.
Population and recruitment
Patients of all ages presenting to study GPs during the reporting period 19 March 2013 to 31 March 2015
(data upload 13 April 2015) with ILI were eligible for inclusion in the study and no exclusion criteria were
applied. LEPIS was activated. Patient recruitment was determined by individual GP convenience rather than
a specific sampling protocol. We estimated a minimum sample size of 1000 patients, assuming an event
rate of 5% (based on the UK mortality and need for interventions in hospitalised influenza patients during
the 2009 A/H1N1pdm2009 pandemic26) to test the hypothesis that the triage tools being tested would
have an AUROC value of > 0.05, demonstrating the ability of the tools to discriminate between patients
who experienced an outcome of interest and those who did not.35,36
Design
Open cohort study involving follow-up for 30 days after the initial consultation for ILI.
Predictor variables
These include criteria from both the adult and child CATs (see Figures 1 and 2) and the adult PMEWS
(see Table 1). Covariates that were extracted from the routine EHRs included patient sociodemographic
characteristics (age, sex), comorbidities associated with an increased influenza risk (cardiovascular disease,
chronic liver disease, neurological conditions, chronic renal disease, chronic respiratory disease, diabetes,
immunosuppressive conditions), previous prescriptions of statins, antibiotics, influenza-specific antivirals, inhaled
and oral corticosteroids, history of seasonal influenza vaccination, pneumococcal vaccination and Haemophilus
influenzae type B vaccination. The detailed code list for disease covariates is provided in Appendix 5.
Outcome variables
There were two primary outcome variables to be collected from the GP EHR: hospital admission within
24 hours of GP assessment (binary categorical variable, coded as yes/no) and death (from all causes)
within 30 days of GP assessment (binary categorical variable, coded as yes/no). Secondary outcome
variables included ‘any need for augmented level of care (admission to high-dependency units or intensive
care units coded as a binary categorical variable)’, length of hospital stay [three binary categorical variables
were created using different thresholds of stay, < 48 hours (yes/no), ≥ 6 days (yes/no), ≥ 12 days (yes/no)],
GP decision to refer to hospital (binary categorical variable, coded as yes/no), GP decision to prescribe
antibiotics (binary categorical variable, coded as yes/no) and GP decision to prescribe influenza-specific
antivirals (binary categorical variable, coded as yes/no).
METHODS
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Statistical analysis (planned and actual)
A descriptive analysis of patient sociodemographic and clinical characteristics was conducted. The planned
analyses included an investigation of the association between each CATs criterion and the various outcome
measures. Each was investigated, in turn, using univariate logistic regression analysis. In addition, a
multivariable model was planned to identify which of the CATs criteria were significant independent
predictors of outcome when included in the same model. A separate investigation of the association
between other covariates (as listed above) and outcomes using a similar approach was also planned. The
analysis plan also considered predictive performance of a combined CATs score (both non-weighted and
weighted, which would incorporate all CATs criteria), as well as the effect of varying individual criteria
and combined score thresholds (e.g. respiratory rate of > 30, > 35, > 40 breaths per minute or a combined
CATs score of > 3, > 4, > 5). Finally, a comparison of predictive performance with the PMEWS score was
planned for adults only. Predictive performance would be assessed using measures including sensitivity,
specificity, positive predictive value, negative predictive value and AUROC curve values. Separate analyses
were run for paediatric and adult patients. All statistical analyses were conducted using Stata.
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Chapter 3 Ethics and consent
The CPRD has been granted generic ethics approval for observational studies that make use of onlyanonymised data and linked anonymised NHS health-care data (Multiple Research Ethics Committee
ref. 05/MRE04/87). All CPRD studies require scientific approval from the MHRA Independent Scientific
Advisory Committee (ISAC). The ISAC was established by the Secretary of State for Health in February
2006 to review the scientific merit of proposals for research using data from the CPRD as well as the
Yellow Card Scheme database.
The clinical assessment data collection tool (or eCRF) was structured to capture evidence-based criteria
recognised in national guidance. The study processes did not require the practitioner to make any change
in their normal assessment; only to record the assessment in a structured manner. ISAC deemed that this
was a non-interventional study and was exempt from the requirement for patient consent as (1) it involved
the development and testing of an IT infrastructure for structured recording of the routine patient
consultation rather than any departures from routine patient care and (2) made use of only linked
anonymised data for analysis. This study protocol was approved by ISAC on 30 May 2012 (ISAC CPRD
Protocol 12_043).
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Chapter 4 Results
Phase 1: set-up of the study, development of the technology
and feasibility
The general architecture of the real-time surveillance system is given in Figure 2. Data relating to each
captured ILI GP consultation were uploaded on the CPRD database every night. The CPRD team then
collated these data and sent weekly data to researchers based at the Universities of Nottingham and
Liverpool. Additionally, on a monthly basis, the CPRD team sent background data (comorbidities,
prescriptions, death, etc.) sourced from the routine electronic primary care record for all patients with
captured ILI consultations. Each subsequent data instalment comprised the cumulative data acquired since
the initiation of the study. The weekly and monthly data sets are described in detail in the FLU-CATs Data
Handbook (see Appendix 6).
The Health and Social Care Information Centre (HSCIC) has responsibility for processing NHS England HES
and linked ONS data since 1 April 2013. The study had permission to obtain 3-monthly HES and ONS
linked data (as described in Data linkage) through existing agreements with HSCIC. HSCIC announced a
delay in issue of HES data on 21 January 2014 for technical reasons and later imposed a moratorium on
release of linked–anonymised data. As of 1 August 2015, CPRD has not received linked–anonymised HES
data from HSCIC despite CPRD and the study investigators satisfying UK permissions. The retention of
HES data by HSCIC has impacted on many research studies including FLU-CATs. It is anticipated that these
validation analyses will be carried out as soon as the HES and ONS data are released to the researchers
prior to the final phase of the study during a pandemic.
Development of real-time analysis and reporting
Three distinct stages of work were required:
1. Data cleaning and management Some data management of the weekly data as provided by CPRD was
necessary to enable analyses. Most of the consultation-specific data collected via the web-based forms
were provided as string variables, and data management mainly involved converting them to numeric
variables or date variables where appropriate. These tasks have been automated and tested for
accuracy in Stata 13 to enable an analyst to complete these usually labour- and time-intensive tasks in
< 10 minutes once the data are received.
2. Analyses After cleaning, the following analyses were planned: descriptive analysis involving tabulation
and summarising of the data; logistic regression analyses (unadjusted and adjusted) to investigate the
association between each of the triage criterions and the primary outcomes; and an assessment of the
predictive performance of different triage tools using AUROC curve comparisons. All analytical tasks
have been automated using Stata 13 and can be completed in < 1 hour by an analyst.
3. Reporting Automated analyses and reporting mechanisms have been set up within Stata to report key
findings from the weekly and monthly data sets. Findings currently being reported include frequency
tables and charts, and results of unadjusted and adjusted logistic regression analyses. Weekly data set
findings are reported in a Microsoft Excel® version 2010 (Microsoft Corporation, Redmond, WA, USA)
spreadsheet and monthly findings in a Microsoft Word® version 2010 (Microsoft Corporation,
Redmond, WA, USA) rich text format (RTF) document. This task has been semi-automated in Stata 13
to facilitate the production of weekly and monthly reports in Word and PDF format for policy-makers.
In addition, a Stata ‘do file’ was developed to extract background data from the CPRD database on
comorbidities and select medication for all patients who underwent a FLU-CATs Study consultation. This
has been tested by the CPRD team and has now been automated to provide the monthly data extracts.
Detailed descriptions of each of the above three steps, along with instructions on how to use the Stata
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‘do files’ are contained in the FLU-CATs Handbook (see Appendix 6). All ‘do files’ have been tested and
validated with each of the weekly and monthly data uploads since the first weekly data tranche was
received on 14 July 2014. The April 2015 data set (13 April 2015 tranche of weekly data) was the last
tranche of data that was analysed at the time of preparation of this report. All findings presented in this
report relate to the FLU-CATs data as of April 2015. Detailed results are provided below (see Phase 2:
pilot study, data collection, extraction and statistical analysis).
Continuous weekly testing of these three processes has allowed us to reduce data management, analytical
and reporting times to 1 day. By adapting the CPRD EHR structure we have also eliminated a separate
electronic data entry step and streamlined data collation while maintaining data security.
We currently do not have sufficient data to report results from the AUROC analyses, even although we
have recruited 863 eligible patients so far because influenza activity has been low and very few of our
patients have progressed to the outcomes of interest.
Data linkage
A ‘do file’ was written to extract relevant variables (hospital admission, need for augmented level of care,
length of stay and death) from HES and ONS data. This ‘do file’ has been tested by the CPRD team using
historic HES and ONS data sets. CPRD have confirmed that the ‘do file’ is automated to periodically extract
HES data for patients with FLU-CATs GP consultations. However, as of April 2015, no HES or ONS linked
data have been received from HSCIC since January 2014. The HES/ONS data received in January 2014
related to the HES period up to the third quarter of 2013 and preceded the first winter influenza season
that this study included. Therefore, validation of the few observed outcome events using the FLU-CATs
pilot study data has not been possible.
Linkage to PHE data sets was explored and abandoned because of inability to anonymously link patients in
CPRD with PHE records with confidence, mostly due to virology requests from primary care not including
sufficient unique patient identifiers. As an alternative solution, linkage is being explored at a practice
and patient level in collaboration with the RCGP Research and Surveillance Centre.
General practitioner participation and user experience
As of April 2015, a total of 30 GP practices participated in the FLU-CATs Study, although at any one time
only 25 GP practices were actively recruiting. There were a total of 704 adult FLU-CATs consultations
(702 single consultations and two repeat consultations) and 159 single consultations for children.
All 30 participating GPs were invited to be interviewed to evaluate the user experience. A total of six GPs
agreed to be interviewed (Table 2). The interviews are summarised below.
TABLE 2 General characteristics of GPs (participating in FLU-CATs Study) who were interviewed
Year qualified Single-/multi-partner practice Location group Location type
1986 Unknown Urban Urban – less sparse
1985 Six partners Urban Urban – less sparse
1984 Two partners Urban Urban – sparse
1979 Two partners Urban Urban – less sparse
1986 Senior partner, three other partners Urban Urban – less sparse
1982 Nine partners Rural Town and fringe – less sparse
RESULTS
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The purpose of conducting these interviews was to explore GPs’ experiences and views of being involved
in a real-time influenza surveillance research project in order to help inform future consultations. GPs who
participated in the FLU-CATs Study were sent invitation letters by CPRD: 11 GPs returned expressions of
interest, of which six were interviewed over telephone. Each interview lasted between 10 and 20 minutes.
A payment of £40 (based on the PCRN recommended rate of £80 per hour) was made to the GPs for their
participation in the qualitative interviews.
The main finding that emerged from these interviews was that the LEPIS trigger pop-up and FLU-CATs
data collection forms were easy to use. The simplicity of the eCRFs encouraged GPs to participate in the
study despite there not being any financial incentive for participation. However, the setting up of the LEPIS
system to enable data collection for the study was fraught with technical difficulties. Although the support
from CPRD in resolving any technical issues surrounding LEPIS installation was appreciated by the GPs,
technical difficulties persisted for some and this reduced patient recruitment. The FLU-CATs process was
quite easy to conduct and did not interfere with the routine GP consultation. All interviewed GPs agreed
that the FLU-CATs system, with a few modifications, was ready to be used in a pandemic scenario.
1. Introduction to, and involvement with, the FLU-CATs Study:
i. Of the six GPs interviewed, three were introduced to the FLU-CATs Study through the research
networks (NIHR PCRN and other local research networks), one through a research coordinator and
one directly by CPRD. The remaining GP did not remember exactly how he/she was introduced to the
study but thought that it might have been through an e-mail.
2. Lack of financial incentive as a barrier to participation:
i. One GP said that the lack of financial incentive for the GPs’ participation in the FLU-CATs Study was
‘inevitably, a barrier’, whereas another GP said that it was not. One GP thought it might have been a
barrier if the FLU-CATs Study was the first ever CPRD study in which the GP was participating but, as
he/she had participated in a few before it was not a barrier for him/her. The consensus among the
interviewed GPs, however, appeared to be that as the FLU-CATs Study was relatively straightforward
and not ‘too onerous’, as one GP put it, the lack of a financial incentive was not a barrier to their
participation. Interestingly, one GP said ‘My partners were a bit reluctant because there was no
remuneration at all, but we thought it was relevant because it was relevant to the influenza season
and I just thought it would focus our minds on how to manage respiratory tract infections’. One GP
said the following about the lack of incentives for participation in the study: ‘I think the only difficulty,
as I was saying at the beginning, with that is it’s a bit difficult to say why would I recommend doing it
and my argument is because it makes me feel like a better person because I do, but does that make
somebody else feel that it makes them feel like a better person if they do. I think the other thing is
if you are thinking about incentives, I don’t think in general practice, the incentive needs to be
particularly large, it just needs to be an appreciation of the fact that there are costs involved in doing
things and the amount of money we got for [another study name] and [another study name], I would
say was well in excess of what was necessary to reimburse us for the amount of work that we had
done. And, I think if you were pitching something like FLU-CAT, looking for a price, then I think
you’d be talking something like a couple of pounds a form not a couple of hundred pounds a form.
Again, I think for the future of CPRD, I don’t think they would have to have terribly large incentives to
make it a reason why people would want to do it. It’s perhaps where there has been some difficulty
about it, it’s just the total lack of an incentive. And, basically, in general practice, if somebody isn’t
paying you anything it’s costing you’.
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3. LEPIS system installation:
i. LEPIS pop-up window According to one GP, this issue was serious enough to affect patient
recruitment significantly: ‘I don’t think it pops up with consultations, so I don’t think we’ve hardly
recruited anybody. So, it’s a real shame because it was easy when it worked, it was dead easy’.
ii. Two GPs reported issues with the clinical IT system Vision while using the LEPIS system. According to
one of them, ‘It was very difficult because we are on EMIS-WEB now but we were on Vision and it
took a long time to get your software to work. Fortunately, we had a medical student who worked
in our office temporarily who was sort of, you know, he was doing a Masters, who was very IT aware
and he spent a lot of time talking to Vision and talking to you and trying to get it working and
eventually he got it to work, but that was a real pain. And, now we’re on EMIS-WEB we can’t do it
all because apparently it doesn’t work with EMIS anyway’. Another issue reported was that the LEPIS
system would ‘hang’ while entering the FLU-CATs form and the GP did not use the system for a
while because she did not want the screen to hang during a consultation. (EMIS® is an alternative
EHR system.)
iii. One recommendation to improve the system was to change the point at which LEPIS was triggered:
‘The biggest problem though I think with it is the fact that what triggers LEPIS is the receiving of the
code not the selecting of the code and I don’t know, I mean I have said this before, that we use DXS
which is the decisions support system and as soon as you select a code it activates DXS but if you
select, let’s say flu-like illness, and then you type to the end of your clinical note, you then save it and
LEPIS triggers, you’re less likely to want to interact with LEPIS than you would be if as soon as you’ve
selected the code flu-like illness, it triggered it. And, that I think is the biggest obstacle to FLU-CAT
being done, where it triggers, because you see by the time it triggers you’ve finished the consultation,
you’ve finished the recording of the consultation and you either decide am I going to bother going
back and doing it. . .I think that’s an inherent problem of the way that LEPIS works at the moment,
that you really want to as soon as you put in that somebody’s got I don’t know, haematuria, you
want it to bring up your haematuria study. You don’t want it to let you write the whole of your
clinical history down and then trigger it’.
iv. Another GP had reported technical difficulties with the LEPIS system, and had stopped recruiting for
the study and intended to resume once the issue was resolved. The GP remarked that he/she would
have found it useful to have received an e-mail or some communication indicating that the issue was
resolved, as he/she had realised the system was fixed only on the morning of the telephone interview
when checked to see if worked.
v. Despite having experienced difficulties with the LEPIS system, all interviewed GPs acknowledged the
support from the CPRD team in helping resolve their technical glitches.
vi. According to the CPRD team member responsible for the web development: ‘Yes, I mean it’s a mixed
bag really, because you find some practices that are computer literate and some of them not
computer literate and so we try to say this is how it works and some of them don’t actually grasp
what’s required for the study, so they would say well it’s not working but they haven’t actually done
the preliminary installation or for example like, if we take the example of the FLU-CATs, because
although there is a wide range of Read-codes, perhaps they put a Read-code which is not in the list,
so therefore obviously it would not pop out to say this patient is eligible . . . Yes, I mean you would
know more than me when you describe the flu, everyone describes it differently, so that’s why we
have included more and more Read-codes because if you. . .what we had done for flu example we
say, oh this is only the ten Read-codes, but perhaps another doctor will describe it differently and it is
another Read-code, although it means the same thing, but it is another Read-code, so we have
worked towards including more Read-codes in order to encompass everything, or we try to educate
. . . a big word educate, you can’t educate a doctor. . .but tell them that basically if they want to
recruit for this study, if you want to take part, this is the list of the Read-codes. So, therefore there is
that communication when you go’.
RESULTS
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4. Nature of the FLU-CATs consultations:
i. All six GPs agreed that the FLU-CATs consultations were very similar to routine consultations and
that the FLU-CATs eCRF was quite easy to complete. One GP said that he/she would fill out the
FLU-CATs form after the consultation with the patient and remarked, ‘I supposed I had to make
note of the blood pressure, which I might not have done had it been a normal viral illness, you know
I wouldn’t necessarily have done that, yes’. Two GPs said they filled out the FLU-CATs forms during
the consultation while the patient was still present. According to one of the GPs, ‘One of the main
people that did our FLU-CATs study returns has been our nurse practitioner and she quite likes it,
it’s quite helpful to her and I mean, I find it’s not at all unhelpful to me, provided I get it triggered at
the right time’.
5. Readiness of the current FLU-CATs system for use by all GPs in a potential pandemic situation:
i. All six GPs thought that the FLU-CATs system would be ready for use in a pandemic situation with
minor modifications. Two GPs expressed the need for the data entry to be better integrated within
their clinical system; according to one of them, ‘I mean it doesn’t take that long. It [FLU-CATs form]
was a couple of minutes extra I guess to do it compared to doing the consultation without it. So, in
the middle of a pandemic that sort of translates to quite a lot of extra work I suppose. If you could
capture straight into the notes without having to sort of. . .it’s a bit faffy at the end, sort of copying
and pasting and it wasn’t the way the data was dropped into the notes would have been fine but
it was pretty much impossible for anyone else to use really. But, otherwise it was okay’.
ii. Another GP thought that the lack of pulse oximeters in every consulting room would need to be
addressed before the FLU-CATs system is recommended for use in a pandemic situation.
iii. All six interviewed GPs said that they would be very interested in reading any outputs that result
from the FLU-CATs Study.
Phase 2: pilot study data collection, extraction and
statistical analysis
To test the existing processes, three outcome measures were studied in the pilot: decision to (1) treat with
influenza-specific antiviral drugs; (2) treat with antibiotics; and (3) refer to hospital. The relatively small
number of deaths reported (which are well captured in primary care data) meant that we did not have
sufficient numbers to look at death as an outcome. The non-availability of ONS data meant that we
were not able to explore the causes of the few cases of death that may be unrelated to influenza. Likewise
we could not assess the secondary outcome measures (such as admission to critical care or length of
hospital stay) expected to be derived from HES data owing to the unavailability of HES data during the
pilot phase.
There were 863 unique FLU-CATs observations in total: 704 adult consultations (702 single and two
repeated) and 159 child consultations. There were 13 (1.8%) deaths in adults and two (1.3%) in children.
GPs decided to refer 11 (1.6%) adults and six (3.8%) children to hospital. In the absence of linked HES
and ONS data it is not possible to validate these results or explore the causes of death.
An important finding from the pilot study was that clinical measures are not consistently measured in all
patients during consultations. In adult patients, temperature was not measured in 32%, respiratory rate
was not measured in 60% and blood pressure was not measured in 74%. Children had a lower proportion
of unmeasured values for temperature, at 14%, and respiratory rate, at 43%. Non-measurement was
not the same as ‘non-assessment’ by the attending clinician; the ‘not measured’ category in clinical
measurements, such as temperature, respiratory rate and heart rate, were further subdivided into
‘not measured as grossly normal’, ‘not measured as grossly abnormal’ and ‘not measured at all’.
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In total, five adults, and no children, were prescribed antiviral drugs. A slightly higher proportion of adults
(73.0%) were recommended treatment with antibiotics compared with children (69.0%). However,
a greater proportion of children (3.8%) were referred to hospital compared with adults (1.6%).
Completeness of data entry and a binary description of clinical variables are given in Table 3.
Descriptive statistics for children and adults are presented in Table 4. As expected, children were observed
to have higher mean and median temperature, respiratory rate and heart rate compared with adults.
TABLE 3 Completeness of data entry and clinical variables by age group
Data item Adults (n= 704), n (%) Children (n= 159), n (%)
Temperature
Measured 479 (68.04) 136 (85.53)
Not measured 225 (31.96) 23 (14.47)
Not measured 133 (18.89) 16 (10.06)
Grossly normal 82 (11.65) 5 (3.14)
Grossly abnormal 10 (1.42) 2 (1.26)
Respiratory ratea
Measured 280 (39.77) 90 (56.60)
Not measured 424 (60.23) 69 (43.40)
Not measured 217 (30.82) 31 (19.50)
Grossly normal 201 (28.55) 38 (23.90)
Grossly abnormal 6 (0.85) 90 (56.60)
Peripheral oxygen saturationb
Measured 417 (59.23) 57 (35.85)
Not measured 287 (40.77) 102 (64.15)
Heart rate
Measured 478 (67.9) 94 (59.12)
Not measured 226 (32.1) 65 (40.88)
Not measured 138 (19.60) 45 (28.30)
Grossly normal 86 (12.22) 20 (12.58)
Grossly abnormal 2 (0.28) 0 (0)
Blood pressure
Measured 182 (25.85) N/A
Not measured 522 (74.15)
Severe respiratory distress
Yes 34 (4.83) 11 (6.92)
No 670 (95.17) 148 (93.08)
Respiratory exhaustion
Yes 10 (1.42) 3 (1.89)
No 694 (98.58) 156 (98.11)
Severe dehydration
Yes 0 0 (0)
No 704 (100) 100 (100)
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
26
TABLE 3 Completeness of data entry and clinical variables by age group (continued )
Data item Adults (n= 704), n (%) Children (n= 159), n (%)
Sternal capillary refill time
Normal 443 (62.93) 102 (64.15)
> 2 seconds 261 (37.07) 57 (35.85)
Patient on oxygen
Yes 1 (0.14) 0 (0)
No 703 (99.86) 159 (100)
Patient on new oxygen
Yes 0 0
No 1 (0.14) 0
N/A 703 (99.86) 100 (100)
New altered consciousness level
No, patient alert 702 (99.72) 157 (98.74)
Confused/agitated 1 (0.14) 2 (1.26)
Responsive to pain only/unconscious (voice for children) 1 (0.14) 0 (0)
Social isolation
Yes 62 (8.81) N/A
No 609 (86.51)
Unknown 33 (4.69)
Activity and ability to self-care
Normal activity, ability to care for self 531 (75.43) N/A
Limited activity, can care for self 104 (14.77)
Housebound, can care for self 11 (1.56)
Housebound, limited self-care 6 (0.85)
Confined, no self-care 5 (0.71)
Not assessed 47 (6.68)
Decision to treat with antivirals
Yes 5 (0.71) 0 (0)
No 699 (99.29) 159 (100)
Decision to treat with antibiotics
Yes 517 (73.44) 110 (69.18)
No 187 (26.56) 49 (30.82)
Decision to refer to hospital
Yes 11 (1.56) 6 (3.77)
No 693 (98.44) 153 (96.23)
N/A, not applicable.
a Where this has not been measured, it has not been possible to derive CAT criterion B.
b For the purpose of deriving CAT criterion C, it has been assumed that a non-measurement suggests a clinical judgement
of ‘grossly normal’.
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The CATs criterion B (increased respiratory rate) could not be determined in 60.2% of adults and 43.4%
of children owing to non-measurement of respiratory rate in these patients. The remaining six CATs criteria
were estimated in all patients. Of these, CATs criterion G (other clinical concern) had the highest
percentage of patients in both adults (21.0%) and in children (22.0%). CATs criterion F (new altered
consciousness) was the least commonly seen criteria, observed in only two adult patients (0.3%)
and two children (1.3%). Descriptive analyses for each of the CATs criteria are presented in Table 5, and
key clinical concerns relating to CATs criterion G are presented in Table 6 (adults) and Table 7 (children).
The association between Community Assessment Tools criteria and
outcomes of interest
The distribution of events across various criteria and covariates resulted in a low number of events in some
categories despite the pilot study reaching nearly 86% of the a priori sample size estimates, and so
running a fully adjusted logistic regression model (adjusting for all confounders) was not possible.
Therefore, an unadjusted and a multivariable model including all of the seven CATs criteria, adjusted for
each other, was run. Generally, because the data were sparse, wide 95% CIs and variable omissions
(from the analyses) were seen. Results from the children’s analyses are presented in Table 8 and results
from the adults’ analyses are presented in Table 9.
TABLE 4 Descriptive analysis of clinical measurements by age group
Clinical measurements Adults (n= 704) Children (n= 159)
Temperature (°C)
Mean (SD) 36.82 (0.71) 37.23 (1.03)
Median (IQR) 36.7 (36.3–37.2) 37.05 (36.45–37.85)
Respiratory rate (breaths per minute)
Mean (SD) 19.69 (5.63) 24.5 (10.52)
Median (IQR) 18 (16–20) 20 (18–28)
Peripheral oxygen value (%)
Mean (SD) 96.94 (2.10) N/A
Median (IQR) 98 (96–98)
Heart rate (beats per minute)
Mean (SD) 83.20 (13.21) 102.02 (22.73)
Median (IQR) 82 (75–90) 100 (80–120)
Systolic blood pressure (mmHg)
Mean (SD) 132.83 (19.32) N/A
Median (IQR) 131.5 (120–143)
Diastolic blood pressure (mmHg)
Mean (SD) 77.11 (10.27) N/A
Median (IQR) 78 (70–84)
IQR, interquartile range; N/A, not applicable; SD, standard deviation.
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TABLE 5 Descriptive analysis of distribution of CATs criteria by age group
Clinical measurements: CATs triage criterion Adults (n= 704), n (%) Children (n= 159), n (%)
A (severe respiratory distress)
Yes 34 (4.83) 11 (6.92)
No 670 (95.17) 148 (93.08)
B (increased respiratory rate)
Yes 4 (0.57) 12 (7.55)
No 276 (39.2) 78 (49.06)
Not measureda 424 (60.23) 69 (43.4)
C (oxygen saturation of ≤ 92%)
Yes 15 (2.13) 7 (4.40)
No 689 (97.87) 152 (95.6)
D (respiratory exhaustion)
Yes 10 (1.42) 3 (1.89)
No 694 (98.58) 156 (98.11)
E (severe clinical dehydration/shock)
Yes 10 (1.42) 5 (3.14)
No 694 (98.58) 154 (96.86)
F (new altered consciousness)
Yes 2 (0.28) 2 (1.26)
No 702 (99.72) 157 (98.74)
G (other clinical concern)
Yes 148 (21.02) 35 (22.01)
No 556 (78.98) 124 (77.99)
a Derived criteria – could not be derived where respiratory rate was not recorded; in children, the respiratory rate threshold
for children aged ≥ 1 year has been used.
TABLE 6 Key themes emerging from free-text comments under ‘nature of other clinical concern’, where available,
presented in order of frequency for adults
Theme Frequency (n)
Other (diabetes, heart disease) 44
Clinical signs suggestive of pneumonia (basal crepitations, rhonchi, crackles, decreased air entry
and consolidation)
39
Chronic lung disease (particularly asthma and chronic obstructive pulmonary disease) 29
Chest pain (pleuritic chest wall pain) 11
Sputum 7
Wheezing 6
Immunosuppression (long-term oral steroid use, other immunosuppressive treatment and
conditions, such as sarcoidosis, which affect the immune system)
6
Prolonged cough (> 4 weeks) 3
Deterioration of symptoms 1
Malignancy 1
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TABLE 7 Key themes emerging from free-text comments under ‘nature of other clinical concern’, where available,
presented in order of frequency for children
Theme Frequency (n)
Clinical signs suggestive of pneumonia 18
Other 9
Chest related 4
Cough 2
Asthma 1
Immunocompromised 1
TABLE 8 Association between CATs criteria and outcomes of interest in children
Outcome
Unadjusted Adjusteda
OR (95% CI) p-value OR (95% CI) p-value
1. Decision to treat with antivirals
CATs criterion A n/a n/a n/a n/a
B n/a n/a n/a n/a
C n/a n/a n/a n/a
D n/a n/a n/a n/a
E n/a n/a n/a n/a
F n/a n/a n/a n/a
G n/a n/a n/a n/a
2. Decision to treat with antibiotics
CATs criterion A 0.51 (0.15 to 1.75) 0.2832 2.96 (0.12 to 70.38) 0.5021
B 0.30 (0.09 to 1.05) 0.0587 0.14 (0.03 to 0.81) 0.0282
C 2.77 (0.32 to 23.64) 0.3519 n/a n/a
D 0.89 (0.08 to 10.04) 0.9241 0.13 (0.002 to 8.35) 0.3392
E n/a n/a n/a n/a
F n/a n/a n/a n/a
G 10.07 (2.31 to 43.92) 0.0021 7.54 (1.12 to 50.92) 0.0382
3. Decision to refer to hospital
CATs criterion A 8.00 (1.29 to 49.68) 0.0256 2.89 (0.02 to 397.44) 0.6731
B 15.40 (1.28 to 185.61) 0.0313 5.19 (0.12 to 234.07) 0.3966
C 14.80 (2.18 to 100.66) 0.0059 39.12 (0.55 to 2759.05) 0.0913
D 15.10 (1.67 to 195.43) 0.0377 19.77 (0.07 to 5498.53) 0.2986
E 7.45 (0.70 to 79.35) 0.0961 n/a n/a
F 30.40 (1.65 to 558.88) 0.0215 n/a n/a
G 3.78 (0.73 to 19.63) 0.1135 1.36 (0.03 to 72.39) 0.8808
n/a, omitted from logistic regression analysis because of insufficient data; OR, odds ratio.
a Adjusted for each of the other CATs criteria.
Statistically significant results are presented in bold text.
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Outcome 1: decision to treat with influenza-specific antiviral drugs
Given that only five adult patients were prescribed influenza-specific antiviral drugs, odds ratios (ORs) and
95% CIs could be obtained for only three criteria in the unadjusted and adjusted analyses. CATs criteria F
and G showed strong positive associations (OR 174.5, 95% CI 9.2 to 3303.9 and OR 15.4, 95% CI 1.7
to 139.0, respectively) in the adjusted analyses, but none of the associations was statistically significant in
the adjusted analyses.
None of the participating GPs decided to treat any of the recruited children with influenza-specific antiviral
drugs, so no further analysis for this outcome was possible for this group.
TABLE 9 Association between CATs criteria and outcomes of interest in adults
Outcome
Unadjusted Adjusteda
OR (95% CI) p-value OR (95% CI) p-value
1. Decision to treat with antivirals
CATs criterion A 5.05 (0.55 to 46.41) 0.1528 5.64 (0.53 to 59.97) 0.1513
B n/a n/a 0.99 (0.79 to 1.24) 0.915
C n/a n/a n/a n/a
D n/a n/a n/a n/a
E n/a n/a n/a n/a
F 174.5 (9.22 to 3303.91) < 0.001 n/a n/a
G 15.42 (1.71 to 139.00) 0.0148 9.88 (0.96 to 101.49) 0.0539
2. Decision to treat with antibiotics
CATs criterion A 1.73 (0.70 to 4.24) 0.2329 1.19 (0.44 to 3.22) 0.7269
B 0.89 (0.86 to 0.93) < 0.001 0.90 (0.87 to 0.94) < 0.001
C 1.46 (0.41 to 5.22) 0.5630 0.96 (0.22 to 4.15) 0.9567
D n/a n/a n/a n/a
E 0.54 (0.15 to 1.92) 0.3310 0.49 (0.12 to 1.99) 0.3178
F 0.36 (0.02 to 5.79) 0.4714 0.09 (0.004 to 1.87) 0.1201
G 6.44 (3.31 to 12.55) < 0.001 6.42 (3.17 to 12.99) < 0.001
3. Decision to refer to hospital
CATs criterion A 28.5 (8.20 to 99.04) < 0.001 26.84 (5.62 to 128.05) < 0.001
B 0.90 (0.78 to 1.03) 0.1303 0.98 (0.82 to 1.17) 0.8272
C 35.43 (9.04 to 138.77) < 0.001 11.67 (1.68 to 81.16) 0.0130
D n/a n/a n/a n/a
E 36.75 (8.03 to 168.29) < 0.001 48.99 (6.06 to 396.32) < 0.001
F 69.20 (4.04 to 1185.94) 0.0034 5.86 (0.003 to 11240.73) 0.6467
G 3.21 (0.96 to 10.65) 0.0573 2.51 (0.55 to 11.46) 0.2350
n/a, omitted from logistic regression analysis because of insufficient data; OR, odds ratio.
a Adjusted for each of the other CATs criteria.
Statistically significant results are presented in bold text.
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Outcome 2: decision to treat with antibiotics
In adults, CATs criteria B and G were statistically significantly associated with this outcome in the
unadjusted analyses, and remained statistically significant with consistent estimates in adjusted analyses.
After adjusting for other CATs criteria, adults presenting with CATs criterion A showed a 10% decreased
odds (95% CI 0.9 to 0.9) of being treated with antibiotics and those presenting with CATs criterion G
were associated with an increased odds of being treated with antibiotics (OR 6.4, 95% CI 3.2 to 13.0).
In children, although CATs criterion G showed a 10-fold increase in odds of treatment with antibiotics
(OR 10.1, 95% CI 2.3 to 43.9) in the unadjusted analyses, this was not seen to be statistically significant
after adjustment for other CATs criteria.
Outcome 3: referral to hospital
In adults, CATs criteria A, C, E and F were positively and statistically significantly associated with referral
to hospital in the unadjusted analyses. CATs criteria C and E remained statistically significant in the
adjusted analyses, with increase in odds of hospital referral by 11.7 times (95% CI 1.7 to 81.2 times) and
49.0 times (95% CI 6.1 to 396.3 times), respectively.
In children, CATs criteria A, D and F were significantly associated with the outcome, although statistical
significance was lost after adjustment for other CATs criteria.
Monthly data findings
Background variables including comorbidities and select treatments/vaccinations were extracted from the
CPRD database for patients with FLU-CATs consultations (coded as ever having had a record of the
comorbidity/treatment/vaccination before the FLU-CATs consultation date). In the 861 total of FLU-CATs
patients, respiratory disease (25.9%) was the most commonly seen comorbidity, followed by diabetes
(8.6%), renal disease (6.6%), cardiovascular disease (5.1%), neurological disease (2.2%), liver disease
(0.4%) and immunosuppression (0.1%). Distribution of comorbidities in adults and children is presented
in Table 10.
Overall, 29.9% of all patients had been prescribed antibiotics, whereas only 0.9% had been prescribed
influenza-specific antiviral drugs at some point before the FLU-CATs consultation. A total of 15.9% of all
patients had past records of seasonal influenza vaccinations. Distribution of treatments and vaccinations in
adults and children is presented in Table 11.
TABLE 10 Distribution of comorbidities by age group
Comorbidity Adult (N= 702a), n (%) Children (N= 159), n (%)
Cardiovascular 41 (4.58) 3 (1.89)
Liver 3 (0.43) 0 (0)
Neurological 17 (2.42) 2 (1.26)
Renal 44 (6.27) 13 (8.18)
Respiratory 209 (29.77) 14 (8.81)
Diabetes 73 (10.40) 1 (0.63)
Immunosuppression 1 (0.14) 0 (0)
a Two adults had repeat consultations hence 704 observations from 702 cases.
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Comparison of Pandemic Medical Early Warning Score with
Community Assessment Tools (adults only)
Given the large number of unmeasured/missing clinical measurements, PMEWS scores could only be
worked out for a small proportion of adult patients in whom all necessary measurements were recorded.
Table 12 shows a comparison of the PMEWS score with the CATs score for the outcomes ‘decision to refer
to hospital’ and ‘death’. Data in this pilot study are too sparse for inferential statistics.
TABLE 11 Distribution of treatments and vaccinations by age group
Drug/vaccination Adult (N= 702a), n (%) Children (N= 159), n (%)
Statin 198 (28.21) N/A
Antibiotic 245 (34.90) 12 (7.55)
Antiviral 7 (1.00) 1 (0.63)
Inhaled steroids 146 (79.20) 9 (5.66)
Oral steroids 248 (35.33) 32 (20.13)
Seasonal influenza vaccine 122 (17.38) 15 (9.43)
Hib vaccine 2 (0.28) 0 (0)
Pneumococcal vaccine 6 (0.85) 0 (0)
Hib, H. influenzae type B; N/A, not applicable.
a Two adults had repeat consultations hence 704 observations from 702 cases.
TABLE 12 Distribution of PMEWS and CATs scores in adults, by primary outcomes
Scores
Refer to hospital (N= 11), n (%) Death (N= 13), n (%)
Yes No Yes No
PMEWS
1 0 (0) 10 (1.44) 0 (0) 10 (1.45)
2 1 (9.09) 14 (2.02) 0 (0) 15 (2.17)
3 0 (0) 15 (2.17) 0 (0) 15 (2.17)
4 0 (0) 7 (1.01) 1 (7.69) 6 (0.87)
5 0 (0) 8 (1.16) 0 (0) 8 (1.16)
6 0 (0) 2 (0.29) 1 (7.69) 1 (0.14)
7 0 (0) 1 (0.14) 0 (0) 1 (0.14)
9 1 (9.09) 1 (0.14) 0 (0) 2 (0.29)
14 1 (9.09) 0 (0) 1 (7.69) 0 (0)
Missing 8 (72.73) 635 (91.63) 10 (76.93) 633 (91.61)
CATs
0 2 (18.18) 171 (24.68) 4 (30.78) 169 (24.46)
1 0 (0) 86 (12.41) 0 (0) 86 (12.45)
2 3 (27.27) 12 (1.73) 2 (15.38) 13 (1.88)
3 0 (0) 4 (0.58) 0 (0) 4 (0.58)
4 2 (18.18) 0 (0) 1 (7.69) 1 (0.14)
Missing 4 (36.37) 420 (60.60) 6 (46.15) 418 (60.49)
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Automated weekly and monthly report generation
Stata ‘do files’ have been written to automate the logistic regression analyses and reporting of the results.
The weekly and monthly ‘do files’ are described in detail in the FLU-CATs Handbook (see Appendix 6).
The weekly results are saved into an Excel spreadsheet with three worksheets – CATs criteria, clinical data
and regression results. Sample screenshots of the weekly report are provided in Figure 7.
FIGURE 7 Sample screenshots of the weekly automated spreadsheet.
RESULTS
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Monthly reports are saved as a RTF Word document containing plots and tables with frequencies of
background CPRD data on comorbidities and treatments. A screenshot of a sample monthly report
document in presented in Figure 8.
FIGURE 8 Sample screenshots of the monthly automated report document.
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Chapter 5 Discussion
Lessons learnt
Phase 1
The CPRD FLU-CATs team identified a number of technical and practical issues during the course of the
feasibility study. These were captured via one-to-one interviews with the study team members and are
listed below:
1. Monetary incentives would be necessary to increase GP participation unless there was a statutory
requirement to systematically collect data on all possible influenza cases during a pandemic.
2. Funding for system maintenance and updating between study phases was not requested in the original
grant. There is a cost associated with keeping the system updated and compliant with the evolving
technological infrastructure, and to facilitate rapid re-activation in case of a pandemic.
3. External issues: bureaucratic processes, which are expected to be resolved in time, stalled provision by
the HSCIC of contemporary HES/ONS linked data. Access to virology data from PHE is unlikely to be
resolved because of lack of adherence to data standards by those requesting virology swabs tests
in the community. Collaboration with the RCGP Research and Surveillance Centre may provide
linked–anonymised virology surveillance data at a practice level and possibly at patient level.
4. Briefing of GPs on the study and LEPIS software installation: installing the LEPIS software was generally
seen as being quite difficult and time intensive for practice staff. Many practices required regular
technical advice from CPRD on this matter. Dedicated IT support is required to aid GPs at set-up.
5. LEPIS did not install at some of the practices, so these GPs were not able to participate in the study.
6. The reorganisation of primary health care from Primary Health Care Trusts to Clinical Commissioning
Groups was associated with preferences for which EHRs are used across Clinical Commissioning Groups.
The popularity of Vision appears to be declining in favour of EMIS. It is estimated that 50% of GPs now
use EMIS. LEPIS does not work on EMIS and so an alternative solution will need to be developed. Thus,
most importantly, to conduct the study in a pandemic situation we would need a flagging system that
could work across several clinical IT systems.
7. Any decision aid based on the validated criteria would better be delivered separately on an open
web-based platform or mobile phone ‘app’.
Phase 2
The two main lessons learnt regarding data analyses relate to missing data, clinical data not being
measured and the delays in obtaining HES and ONS linkage data.
1. Missing clinical measurements Up to 74% of some clinical measurements (blood pressure in adults in
this instance), were not recorded as part of GPs’ routine assessment of an adult person presenting with
ILI. We would question the utility and adoption of triage tools that depend upon a clinical measurement
that is not used in the routine assessment of ILI for use in a time-pressured pandemic situation.
During the early phases of the pilot study, the low recording of clinical measurements prompted the
researchers to modify the form to include two further categories: ‘not measured – grossly normal’ and
‘not measured – grossly abnormal’. This was based on informal feedback that the clinical examination
did consider factors such as fever, respiratory rate, blood pressure, etc., but that formal measurements
were triggered only if they appeared to be grossly abnormal. Our study was not an interventional study
and therefore tried to approximate the ‘routine’ clinical consultation. Although failure of exact
measurements resulted in poor recording of PMEWS criteria, we were able to derive the CATs criteria
for the majority of patients. Therefore, it is reasonable to assume that CATs offers a more user-friendly
and efficient option for GPs over a more data-intensive triage tool such as PMEWS.
DOI: 10.3310/hta19890 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 89
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Venkatesan et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
37
2. Linkage with HES and ONS In the absence of contemporary linked data from HES and ONS, it was not
possible to prospectively validate the primary outcomes (hospital admission and death) or study
secondary outcomes (e.g. admission to intensive care, length of hospital stay) or examine cause of
death. However, it is important to note that the CPRD primary care data routinely records death data
and hospital admissions, so while there may be a slight underestimation of these data, it would still be
possible to study these outcomes using primary care data alone (although possibly with a 1-month lag
without active follow-up of flagged patients).
The LEPIS software and accompanying web-based data collection form have generally been regarded as
being quick and easy to use after the initial set-up, taking an experienced user about a minute to
complete. However, the research team has identified a number of limitations. One is that the LEPIS
software is specific to GP practices that use the Vision system and incompatible with GP practices using
EMIS, SystmOne® (Horsforth, Leeds, UK) or other EHR systems. Although the popularity of Vision is
reducing, there are still about 650 practices using this system and contributing to CPRD. If all of these GPs
could be deployed in the event of a pandemic, there could be a population-based surveillance system
providing near real-time reports of the course of the pandemic. There were technical problems with
compatibility of the LEPIS software with some configurations of the GP computer systems, which need to
be resolved. Moreover, although being very easy to use, LEPIS was seen as being quite difficult to set up,
and technical assistance was necessary to help GPs to install the system. Both of these points are important
limitations that would prevent a rapid national level rollout using the existing LEPIS software to trigger data
collection. A decision aid based on the validated criteria would better be delivered separately on an open
web-based platform or mobile phone ‘app’.
A lack of any financial incentive was cited by several practices as a reason for not participating. Several GPs
felt that even a minimal payment of a few pounds would be sufficient remuneration for the research
activity. We will add a small payment for each case submitted in future seasons.
This study is one of the UK NIHR portfolio of pandemic preparedness studies. The investigators are funded
to establish capacity and processes during an inter-pandemic period in readiness to run the study during
the early stages of a future outbreak of pandemic influenza or other outbreak of severe acute respiratory
infection of public health concern. Our results show that a web-based triage tool, which uses simple
clinical assessments, can be used with ease during routine consultations, and that linkage to the patient’s
EHR with automated background processes can be used to define the performance of triage criteria triage
tool against outcome events. Using the processes that we have developed, the demonstration of the proof
of concept indicates that the study will be of value during the early phases of a novel pandemic and
capable of providing a valid triage tool in readiness for surge. If surge occurs, the web-based process could
be switched from data collation to provide a decision aid. This would best be provided on common
web-based platforms or mobile phone ‘apps’.
To scale up the study during a pandemic period will be challenging, as we recognise that about half of
willing CPRD practices in the pilot had difficulties installing the LEPIS software, and half of all practices in
England and Wales use a different EHR system. That said, the EMIS system also has capability to monitor
consultations and trigger to structured data entry forms. The investigators are in negotiation with EMIS
to develop a solution for that system.
This study adheres to the five principles of Dynamic Risk Assessment, as applied to the management of
emergency situations by UK Government agencies (Evaluate, Select, Assess, Refine, Reassess).37 That said,
the proposed use of triage tools by the NHS in the UK during pandemic surge has been criticised, in
particular because of lack of evidence of engagement with the general population and with local
ethics committees.38
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The data collection period of the study to date covers two calendar years, including the set-up and pilot in
sequential winter seasons. At most, only 25 GPs were recruiting cases. PHE described influenza activity
in the UK as low in 2013–14 and moderate in 2014–15.39 Perhaps as a result of these factors, and the
low-to-moderate influenza activity, only a few of the 863 patients had primary outcomes of interest
(death n= 15 and referral to hospital for admission n= 17).
It is possible that GPs chose to ignore the LEPIS prompts when patients with severe illness presented, thus
introducing bias to the study. However, the hospital referral rate observed for this study of 19.7 per
1000 consultations is within the ranges quoted for several larger studies that examine variation in GP
referral rates in the UK.40
A potential limitation of studies such as this relates to possible misclassification of criteria as a result of
clinicians’ preference to record only certain important negative or positive features. We avoided
misclassification of data seen in our previous studies by use of required data entry fields with
exclusive options.
This was a non-interventional study. Although the clinical assessment data collection tool (eCRF) was
structured to capture evidence-based criteria, recognised in national guidance, it did not require the
practitioner to make any change in his/her normal assessment – only to record the assessment. We
thought that the presentation of a structured assessment form may result in personal reflection on the
nature of the GP’s own assessment and so alter the completeness of future assessments. We were
therefore surprised to find that some clinical measures are not consistently taken with many patients
during consultations. Three-quarters of adults did not have their blood pressure taken, and 60% of adults
and 43% of children did not have their respiratory rate measured. Our data collection system did allow
GPs to record some clinical assessments, such as respiratory rate, as ‘not measured as grossly normal’ and
‘not measured as grossly abnormal’, which reflects pragmatic or usual practice. This finding is important,
as it strongly suggests that criteria that rely upon a measurement such as blood pressure, and which is not
being used consistently in routine assessment of ILI, should not be included in a triage tool that is designed
for use during surge, when time and resources are in even shorter supply.
Denial of access to linked HES and ONS data by the HSCIC has meant that, at the time of writing, it has
not been possible to validate the primary outcomes (admission to hospital and death) or secondary
outcomes (admission to intensive care and length of hospital stay). A retrospective analysis of the existing
data will be possible when the linked data are made available.
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Chapter 6 Conclusions
The use of EHRs linked to background analytical processes allows near real-time analysis of GPassessments, management decisions and patients’ outcomes. The processes are dynamic and should
allow refinement of triage criteria in the early stages of a future outbreak.
To be prepared, the study is continuing in pilot phase, as it is essential to maintain processes in an
environment where EHRs and database processes are continually evolving. Future work will include
exploring if minimal remuneration will improve recruitment, development of processes to include other
EHR systems; and attempting to link to data on influenza surveillance at a practice and patient level.
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Appendix 1 List of Read codes used to identify
potential influenza cases in Hospital Episode
Statistics data
H2z..00 Pneumonia or influenza NOS
H2..00 Pneumonia and Influenza
16L..00 Influenza-like symptoms
H2y..00 Other specified pneumonia or influenza
H2A..11 Influenza A(H1N1) swine flu
H2A..00 Influenza due to Influenza A virus subtype H1N1
4JU0.00 Influenza H1 virus detected
H051. Acute upper respiratory tract infection
H05z. Upper respiratory tract infection (URTI)
1W0..00 Possible Influenza A virus H1N1 subtype
1J72.11 Suspected swine influenza
1J72.00 Suspected Influenza A virus subtype H1N1 infection
Hyu0700 [X] Influenza+ other manifestations, virus not identified
Hyu0600 [X] Influenza+ other respiratory manifestations, virus not identified
43k2.00 Influenza A antigen level
43dF.00 Influenza A antibody level
G520300 Acute myocarditis – influenza
4JU4.00 Influenza A virus, other or untyped strain detected
H29..00 Avian influenza
Hyu0500 [X] Influenza+ other manifestations, influenza virus identified
H27.. Influenza
H27z.12.Influenza like illness (ILL)
H27y100 Influenza with gastrointestinal tract involvement
H271z00 Influenza with Respiratory manifestations
H270000 Influenza with bronchopneumonia
H271000 Influenza with laryngitis
H271100 Influenza with pharyngitits
H270.00 Influenza with pneumonia
H270z00 Influenza with pneumonia NOS
H270.11 Chest infection – influenza with pneumonia
H271.00 Influenza with other respiratory manifestation
H27y.00 Influenza with other manifestations
H27yz00 Influenza with other manifestations NOS
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H27y000 Influenza with encephalopathy
4JU5.00 Influenza B virus detected
43k3.00 Influenza B antigen level
H270100 Influenza with pneumonia, influenza virus identified
4JU2.00 Influenza H3 virus detected
4JU3.00 Influenza H5 virus detected
4J3M.00 Influenza A virus H1N1 subtype not detected
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Appendix 2 Influenza-related Read codes used by
general practitioners for patient assessment prior to
an admission to hospital with a discharge diagnosis
of influenza and chosen to trigger Local Eligibility
Patient Identification Software
Rank Read code Read code descriptor Patients, n= 471 Frequency (%)
1 H27z.11 Flu-like illness 72 15.5
2 H27..00 Influenza 70 15.0
3 H06z011 Chest infection 60 12.9
4 H2A..11 Influenza A (H1N1) swine flu 52 11.2
5 H06z000 Chest infection NOS 41 8.8
6 H26..00 Pneumonia due to unspecified organism 27 5.8
7 H061.00 Acute bronchiolitis 19 4.1
8 H06z100 Lower resp tract infection 14 3.0
9 H2y..00 Other specified pneumonia or influenza 12 2.6
10 H2z..00 Pneumonia or influenza NOS 11 2.4
11 16L..00 Influenza-like symptoms 9 1.9
12 H06z111 Respiratory tract infection 8 1.7
13 1J72.11 Suspected swine influenza 7 1.5
14 H2...00 Pneumonia and influenza 7 1.5
15 H2A..00 Influenza due to Influenza A virus subtype H1N1 7 1.5
16 H062.00 Acute lower respiratory tract infection 6 1.3
17 H21..00 Lobar (pneumococcal) pneumonia 6 1.3
18 H27z.00 Influenza NOS 5 1.1
19 H25..00 Bronchopneumonia due to unspecified organism 4 0.9
20 1W0..00 Possible influenza A virus H1N1 subtype 3 0.6
21 H0...00 Acute respiratory infections 3 0.6
22 H060.00 Acute bronchitis 3 0.6
23 H20..00 Viral pneumonia 3 0.6
24 H260.00 Lobar pneumonia due to unspecified organism 2 0.4
25 H260000 Lung consolidation 2 0.4
26 H261.00 Basal pneumonia due to unspecified organism 2 0.4
27 H27z.12 Influenza like illness 2 0.4
28 H28..00 Atypical pneumonia 2 0.4
29 H5yy.11 Respiratory infection NOS 2 0.4
30 1J72.00 Suspected influenza A virus subtype H1N1 infection 1 0.2
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Rank Read code Read code descriptor Patients, n= 471 Frequency (%)
31 H20z.00 Viral pneumonia NOS 1 0.2
32 H22..00 Other bacterial pneumonia 1 0.2
33 H22z.00 Bacterial pneumonia NOS 1 0.2
34 H23..00 Pneumonia due to other specified organisms 1 0.2
35 H270000 Influenza with bronchopneumonia 1 0.2
36 H270100 Influenza with pneumonia, influenza virus identified 1 0.2
37 H27y.00 Influenza with other manifestations 1 0.2
38 H30..00 Bronchitis unspecified 1 0.2
39 H301.00 Laryngotracheobronchitis 1 0.2
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Appendix 3 Stata algorithms for data
management and analysis ‘do files’
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Appendix 4 Semistructured interview guide used
to evaluate general practitioner user experience of
study technological interface
Introduction l Introduce interviewer and state the aim of the study
l Aim: To explore GPs’ perspectives on participation in real-time surveillance study in
collaboration with CPRD
l Mention that the call will be recorded
l Obtain consent
Decision to participate in
the Flu-CATs
l Who were you approached by to participate in the Flu-CATs?
l Motivation to participate in the FLU-CATs project?
l Any personal benefit?
l Any barriers to participation?
Setting up the LEPIS system l The general experience of having the LEPIS system set-up:
¢ How long did it take?
¢ Were there any problems setting it up? Prompt to obtain more detail
The Flu-CATs consultation l Roughly how long did each FLU-CATs consultation last?
l Was it different when compared to a ‘routine’ GP consultation? If so, how?
l Were there any challenges in recording FLU-CATs-related clinical measurements?
¢ Was any particular CATs criterion more difficult to record than others?
l How was your experience of using the LEPIS system?
l Is there any other clinical parameter that you think might shed insight into
influenza-related severe outcomes?
Thoughts/reflections l Implementing this in a real pandemic scenario:
¢ How feasible do you think it is?
¢ Do you think FLU-CATs consultations would be different in a pandemic scenario
when compared to now (seasonal flu)?
l Is there anything you would like see improved?
l Would you be willing to participate in the FLU-CATs again (Winter of 2014–15)?
l Would you be interested in the reading the outputs from the FLU-CATs project?
l Is there anything else that you would like to add?
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Appendix 5 Covariate code lists
Read code Read term
History of cardiovascular disease at any point previous to the study consultation
G3...00 Ischaemic heart disease
G580.00 Congestive heart failure
G3...13 IHD - Ischaemic heart disease
G58..00 Heart failure
G3z..00 Ischaemic heart disease
G58z.00 Heart failure NOS
P6z..00 Congenital heart anomaly NOS
G580100 Chronic congestive heart failure
G580.12 Right heart failure
G3y..00 Other specified ischaemic heart disease
G34..00 Other chronic ischaemic heart disease
P6...00 Other congenital heart anomalies
G34z.00 Other chronic ischaemic heart disease NOS
P6z3.00 Cyanotic congenital heart disease NOS
G342.00 Atherosclerotic cardiovascular disease
P6y5.00 Congenital heart block
P5...12 Congenital heart disease, septal and bulbar anomalies
P6zz.00 Congenital heart anomaly NOS
P68..00 Congenital heart disease
G34y.00 Other specified chronic ischaemic heart disease
G583.00 Heart failure with normal ejection fraction
G34yz00 Other specified chronic ischaemic heart disease NOS
P6z2.00 Acyanotic congenital heart disease NOS
G580400 Congestive heart failure due to valvular disease
G583.11 HFNEF - heart failure with normal ejection fraction
Gyu3300 [X]Other forms of chronic ischaemic heart disease
P6y5000 Congenital heart block, unspecified
P6y5z00 Congenital heart block NOS
Gyu5g00 [X]Cardiovascular disease, unspecified
History of chronic liver disease at any point previous to the study consultation
J61..00 Cirrhosis and chronic liver disease
J614.00 Chronic hepatitis
J61z.00 Chronic liver disease NOS
J614z00 Chronic hepatitis NOS
J62..00 Liver abscess and sequelae of chronic liver disease
PB61.00 Biliary atresia
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Read code Read term
J61y.00 Other non-alcoholic chronic liver disease
J62y.00 Other sequelae of chronic liver disease
J61yz00 Other non-alcoholic chronic liver disease NOS
J614y00 Chronic hepatitis unspecified
PB61z00 Biliary atresia NOS
History of chronic neurological disease at any point previous to the study consultation
G66..00 Stroke and cerebrovascular accident unspecified
G65..12 Transient ischaemic attack
F20..00 Multiple sclerosis
F23..00 Congenital cerebral palsy
G66..12 Stroke unspecified
G64..13 Stroke due to cerebral arterial occlusion
G61..12 Stroke due to intracerebral haemorrhage
G664.00 Cerebellar stroke syndrome
G663.00 Brain stem stroke syndrome
F230100 Cerebral palsy with spastic diplegia
F23..11 Congenital spastic cerebral palsy
F137000 Athetoid cerebral palsy
F23z.00 Congenital cerebral palsy NOS
F23..12 Infantile cerebral palsy
G669.00 Cerebral palsy, not congenital or infantile, acute
F207.00 Relapsing and remitting multiple sclerosis
F23y200 Spastic cerebral palsy
F208.00 Secondary progressive multiple sclerosis
F23y400 Ataxic diplegic cerebral palsy
F23y000 Ataxic infantile cerebral palsy
F23yz00 Other infantile cerebral palsy NOS
F202.00 Generalised multiple sclerosis
F206.00 Primary progressive multiple sclerosis
F23y300 Dyskinetic cerebral palsy
F23y.00 Other congenital cerebral palsy
F200.00 Multiple sclerosis of the brain stem
Fyu9.00 [X]Cerebral palsy and other paralytic syndromes
F201.00 Multiple sclerosis of the spinal cord
Fyu9000 [X]Other infantile cerebral palsy
F137.11 Athetoid cerebral palsy
F29y100 Postpolio syndrome
F23y100 Flaccid infantile cerebral palsy
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History of chronic renal disease at any point previous to the study consultation
1Z12.00 Chronic kidney disease stage 3
K05..00 Chronic renal failure
1Z13.00 Chronic kidney disease stage 4
K01..00 Nephrotic syndrome
1Z15.00 Chronic kidney disease stage 3A
1Z1C.00 Chronic kidney disease stage 3 without proteinuria
1Z1E.00 Chronic kidney disease stage 3A without proteinuria
1Z14.00 Chronic kidney disease stage 5
1Z16.00 Chronic kidney disease stage 3B
K0Z..00 Nephritis, nephrosis and nephrotic syndrome NOS
1Z1G.00 Chronic kidney disease stage 3B without proteinuria
1Z1B.00 Chronic kidney disease stage 3 with proteinuria
ZV42000 [V]Kidney transplanted
K0…00 Nephritis, nephrosis and nephrotic syndrome
1Z1J.00 Chronic kidney disease stage 4 without proteinuria
1Z1D.00 Chronic kidney disease stage 3A with proteinuria
1Z1H.00 Chronic kidney disease stage 4 with proteinuria
1Z1F.00 Chronic kidney disease stage 3B with proteinuria
K011.00 Nephrotic syndrome with membranous glomerulonephritis
K01z.00 Nephrotic syndrome NOS
1Z1K.00 Chronic kidney disease stage 5 with proteinuria
K01x100 Nephrotic syndrome in diabetes mellitus
TB00111 Renal transplant with complication, without blame
K013.00 Nephrotic syndrome with minimal change glomerulonephritis
K015.00 Nephrotic syndrome, focal and segmental glomerular lesions
K016.00 Nephrotic syndrome, diffuse membranous glomerulonephritis
1Z1L.00 Chronic kidney disease stage 5 without proteinuria
K01x000 Nephrotic syndrome in amyloidosis
K014.00 Nephrotic syndrome, minor glomerular abnormality
K013.12 Steroid sensitive nephrotic syndrome
K01x400 Nephrotic syndrome in systemic lupus erythematosus
K01B.00 Nephrotic syndrome, diffuse crescentic glomerulonephritis
TB00100 Kidney transplant with complication, without blame
K0y..00 Other specified nephritis, nephrosis or nephrotic syndrome
K01w.00 Congenital nephrotic syndrome
K010.00 Nephrotic syndrome with proliferative glomerulonephritis
K01A.00 Nephrotic syndrome, dense deposit disease
Kyu2100 [X]Other chronic renal failure
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Read code Read term
K01x300 Nephrotic syndrome in polyarteritis nodosa
K01y.00 Nephrotic syndrome with other pathological kidney lesions
K012.00 Nephrotic syndrome+membranoproliferative glomerulonephritis
History of chronic respiratory disease at any point previous to the study consultation
H33..00 Asthma
H3...00 Chronic obstructive pulmonary disease
H333.00 Acute exacerbation of asthma
H33zz00 Asthma NOS
H33z100 Asthma attack
H34..00 Bronchiectasis
H36..00 Mild chronic obstructive pulmonary disease
H33..11 Bronchial asthma
H32..00 Emphysema
H33z011 Severe asthma attack
H31..00 Chronic bronchitis
H38..00 Severe chronic obstructive pulmonary disease
H330.00 Extrinsic (atopic) asthma
H330.12 Childhood asthma
663V100 Mild asthma
C370.00 Cystic fibrosis
H330.11 Allergic asthma
663V200 Moderate asthma
H331.00 Intrinsic asthma
1O2..00 Asthma confirmed
H330011 Hay fever with asthma
H330.13 Hay fever with asthma
H331.11 Late onset asthma
H31z.00 Chronic bronchitis NOS
H33z000 Status asthmaticus NOS
H58y300 Interstitial lung disease NEC
H330.14 Pollen asthma
H330111 Extrinsic asthma with asthma attack
H330000 Extrinsic asthma without status asthmaticus
H33z200 Late-onset asthma
663V300 Severe asthma
H33z111 Asthma attack NOS
H310000 Chronic catarrhal bronchitis
H312000 Chronic asthmatic bronchitis
H34z.00 Bronchiectasis NOS
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H312100 Emphysematous bronchitis
H39..00 Very severe chronic obstructive pulmonary disease
H45..00 Pneumoconiosis NOS
H32z.00 Emphysema NOS
H330z00 Extrinsic asthma NOS
H3z..11 Chronic obstructive pulmonary disease NOS
Q317000 Perinatal bronchopulmonary dysplasia
H334.00 Brittle asthma
H312011 Chronic wheezy bronchitis
H43z.00 Pneumoconiosis due to inorganic dust NOS
H320.00 Chronic bullous emphysema
H331000 Intrinsic asthma without status asthmaticus
H331z00 Intrinsic asthma NOS
H340.00 Recurrent bronchiectasis
H311.00 Mucopurulent chronic bronchitis
C370z00 Cystic fibrosis NOS
66Yi.00 Multiple COPD emergency hospital admissions
H330100 Extrinsic asthma with status asthmaticus
A115.00 Tuberculous bronchiectasis
H40..00 Coal workers’ pneumoconiosis
C370200 Cystic fibrosis with pulmonary manifestations
H322.00 Centrilobular emphysema
SK07.00 Subcutaneous emphysema
H581.00 Interstitial emphysema
H331111 Intrinsic asthma with asthma attack
H33zz12 Allergic asthma NEC
Q317.00 Perinatal chronic respiratory disease
H591.00 Chronic respiratory failure
H320z00 Chronic bullous emphysema NOS
H341.00 Post-infective bronchiectasis
H331100 Intrinsic asthma with status asthmaticus
H42z.00 Silica pneumoconiosis NOS
H31y100 Chronic tracheobronchitis
H32yz00 Other emphysema NOS
Hyu3100 [X]Other specified chronic obstructive pulmonary disease
H311000 Purulent chronic bronchitis
H42..00 Silica and silicate pneumoconiosis
H32y.00 Other emphysema
H310z00 Simple chronic bronchitis NOS
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H313.00 Mixed simple and mucopurulent chronic bronchitis
H32y200 MacLeod’s unilateral emphysema
H464.00 Chronic respiratory conditions due to chemical fumes
Q317z00 Perinatal chronic respiratory disease NOS
P861.00 Congenital bronchiectasis
H321.00 Panlobular emphysema
H320200 Giant bullous emphysema
H31y.00 Other chronic bronchitis
H31yz00 Other chronic bronchitis NOS
H43..00 Pneumoconiosis due to other inorganic dust
Q312.00 Perinatal interstitial emphysema and related conditions
H320000 Segmental bullous emphysema
H320100 Zonal bullous emphysema
C370100 Cystic fibrosis with meconium ileus
H582.00 Compensatory emphysema
C370y00 Cystic fibrosis with other manifestations
C370300 Cystic fibrosis with intestinal manifestations
Hyu3000 [X]Other emphysema
H320300 Bullous emphysema with collapse
H4y2100 Chronic drug-induced interstitial lung disorders
Q317y00 Other specified perinatal chronic respiratory disease
Q312111 Perinatal mediastinal emphysema
H464000 Chronic emphysema due to chemical fumes
H3y..11 Other specified chronic obstructive pulmonary disease
C370500 Cystic fibrosis with distal intestinal obstruction syndrome
H450.00 Pneumoconiosis associated with tuberculosis
H311100 Fetid chronic bronchitis
H420.00 Talc pneumoconiosis
H32y100 Atrophic (senile) emphysema
C370400 Arthropathy in cystic fibrosis
H32y111 Acute interstitial emphysema
C370000 Cystic fibrosis with no meconium ileus
H464z00 Chronic respiratory conditions due to chemical fumes NOS
H32y000 Acute vesicular emphysema
C370800 Cystic fibrosis related cirrhosis
History of diabetes at any point previous to the study consultation
C10..00 Diabetes mellitus
C10F.00 Type 2 diabetes mellitus
C100112 Non-insulin dependent diabetes mellitus
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C109.00 Non-insulin dependent diabetes mellitus
C10E.00 Type 1 diabetes mellitus
C109.12 Type 2 diabetes mellitus
C100011 Insulin dependent diabetes mellitus
C100111 Maturity onset diabetes
C100100 Diabetes mellitus, adult onset, no mention of complication
C101.00 Diabetes mellitus with ketoacidosis
C10FJ00 Insulin treated Type 2 diabetes mellitus
C106.00 Diabetes mellitus with neurological manifestation
C106.12 Diabetes mellitus with neuropathy
C108.11 IDDM-Insulin dependent diabetes mellitus
C10FM00 Type 2 diabetes mellitus with persistent microalbuminuria
C108.12 Type 1 diabetes mellitus
C109.11 NIDDM - Non-insulin dependent diabetes mellitus
C109.13 Type II diabetes mellitus
C10EM00 Type 1 diabetes mellitus with ketoacidosis
C109J00 Insulin treated Type 2 diabetes mellitus
C10FL00 Type 2 diabetes mellitus with persistent proteinuria
C10F.11 Type II diabetes mellitus
C10FC00 Type 2 diabetes mellitus with nephropathy
C10F600 Type 2 diabetes mellitus with retinopathy
C107.00 Diabetes mellitus with peripheral circulatory disorder
C105.00 Diabetes mellitus with ophthalmic manifestation
C104.00 Diabetes mellitus with renal manifestation
66AJ.11 Unstable diabetes
C108.13 Type I diabetes mellitus
C10F900 Type 2 diabetes mellitus without complication
C10E.12 Insulin dependent diabetes mellitus
C10FN00 Type 2 diabetes mellitus with ketoacidosis
C100z00 Diabetes mellitus NOS with no mention of complication
C108900 Insulin dependent diabetes maturity onset
C10EK00 Type 1 diabetes mellitus with persistent proteinuria
C10ED00 Type 1 diabetes mellitus with nephropathy
C10E700 Type 1 diabetes mellitus with retinopathy
C10EL00 Type 1 diabetes mellitus with persistent microalbuminuria
C10FK00 Hyperosmolar non-ketotic state in type 2 diabetes mellitus
C101z00 Diabetes mellitus NOS with ketoacidosis
C104z00 Diabetes mellitus with nephropathy NOS
C11y000 Steroid induced diabetes
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C10D.00 Diabetes mellitus autosomal dominant type 2
C107.11 Diabetes mellitus with gangrene
C106z00 Diabetes mellitus NOS with neurological manifestation
C108700 Insulin dependent diabetes mellitus with retinopathy
C109900 Non-insulin-dependent diabetes mellitus without complication
C109400 Non-insulin dependent diabetes mellitus with ulcer
K01x100 Nephrotic syndrome in diabetes mellitus
C108500 Insulin dependent diabetes mellitus with ulcer
C10E.11 Type I diabetes mellitus
C106100 Diabetes mellitus, adult onset, + neurological manifestation
C10EN00 Type 1 diabetes mellitus with ketoacidotic coma
C10G.00 Secondary pancreatic diabetes mellitus
C10FB00 Type 2 diabetes mellitus with polyneuropathy
C105z00 Diabetes mellitus NOS with ophthalmic manifestation
C10F911 Type II diabetes mellitus without complication
C10F000 Type 2 diabetes mellitus with renal complications
C10FQ00 Type 2 diabetes mellitus with exudative maculopathy
C10C.11 Maturity onset diabetes in youth
C10FH00 Type 2 diabetes mellitus with neuropathic arthropathy
C10F200 Type 2 diabetes mellitus with neurological complications
C10EQ00 Type 1 diabetes mellitus with gastroparesis
C10FE00 Type 2 diabetes mellitus with diabetic cataract
C109600 Non-insulin-dependent diabetes mellitus with retinopathy
C10B000 Steroid induced diabetes mellitus without complication
C10F400 Type 2 diabetes mellitus with ulcer
C107.12 Diabetes with gangrene
Cyu2.00 [X]Diabetes mellitus
C105100 Diabetes mellitus, adult onset, + ophthalmic manifestation
C10FR00 Type 2 diabetes mellitus with gastroparesis
C10zz00 Diabetes mellitus NOS with unspecified complication
C10FJ11 Insulin treated Type II diabetes mellitus
C101000 Diabetes mellitus, juvenile type, with ketoacidosis
C10EE00 Type 1 diabetes mellitus with hypoglycaemic coma
C106000 Diabetes mellitus, juvenile, + neurological manifestation
C107z00 Diabetes mellitus NOS with peripheral circulatory disorder
C10FD00 Type 2 diabetes mellitus with hypoglycaemic coma
C106.13 Diabetes mellitus with polyneuropathy
C108400 Unstable insulin dependent diabetes mellitus
C10z.00 Diabetes mellitus with unspecified complication
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C10y.00 Diabetes mellitus with other specified manifestation
C10FA00 Type 2 diabetes mellitus with mononeuropathy
C10FL11 Type II diabetes mellitus with persistent proteinuria
C10F100 Type 2 diabetes mellitus with ophthalmic complications
C10EP00 Type 1 diabetes mellitus with exudative maculopathy
C109C00 Non-insulin dependent diabetes mellitus with nephropathy
C10N100 Cystic fibrosis related diabetes mellitus
C10ER00 Latent autoimmune diabetes mellitus in adult
C10z100 Diabetes mellitus, adult onset, + unspecified complication
C108E00 Insulin dependent diabetes mellitus with hypoglycaemic coma
C10EJ00 Type 1 diabetes mellitus with neuropathic arthropathy
C10EA00 Type 1 diabetes mellitus without complication
C104100 Diabetes mellitus, adult onset, with renal manifestation
L180600 Pre-existing diabetes mellitus, non-insulin-dependent
C10F500 Type 2 diabetes mellitus with gangrene
C10E500 Type 1 diabetes mellitus with ulcer
C10E900 Type 1 diabetes mellitus maturity onset
C107200 Diabetes mellitus, adult with gangrene
C10E400 Unstable type 1 diabetes mellitus
C10FF00 Type 2 diabetes mellitus with peripheral angiopathy
C10E000 Type 1 diabetes mellitus with renal complications
C101100 Diabetes mellitus, adult onset, with ketoacidosis
C109J12 Insulin treated Type II diabetes mellitus
C107100 Diabetes mellitus, adult, + peripheral circulatory disorder
C10E300 Type 1 diabetes mellitus with multiple complications
C10F611 Type II diabetes mellitus with retinopathy
C108000 Insulin-dependent diabetes mellitus with renal complications
C10FG00 Type 2 diabetes mellitus with arthropathy
C10F300 Type 2 diabetes mellitus with multiple complications
C102100 Diabetes mellitus, adult onset, with hyperosmolar coma
C10FP00 Type 2 diabetes mellitus with ketoacidotic coma
C10D.11 Maturity onset diabetes in youth type 2
C10EM11 Type I diabetes mellitus with ketoacidosis
C10E200 Type 1 diabetes mellitus with neurological complications
C101y00 Other specified diabetes mellitus with ketoacidosis
C109411 Type II diabetes mellitus with ulcer
C10EC00 Type 1 diabetes mellitus with polyneuropathy
C109J11 Insulin treated non-insulin dependent diabetes mellitus
C10EF00 Type 1 diabetes mellitus with diabetic cataract
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C108A00 Insulin-dependent diabetes without complication
C106y00 Other specified diabetes mellitus with neurological comps
C109100 Non-insulin-dependent diabetes mellitus with ophthalm comps
C109000 Non-insulin-dependent diabetes mellitus with renal comps
C108512 Type 1 diabetes mellitus with ulcer
C108E11 Type I diabetes mellitus with hypoglycaemic coma
C109612 Type 2 diabetes mellitus with retinopathy
C109200 Non-insulin-dependent diabetes mellitus with neuro comps
C108D00 Insulin dependent diabetes mellitus with nephropathy
C109212 Type 2 diabetes mellitus with neurological complications
C10E100 Type 1 diabetes mellitus with ophthalmic complications
C108100 Insulin-dependent diabetes mellitus with ophthalmic comps
C109412 Type 2 diabetes mellitus with ulcer
C109E00 Non-insulin depend diabetes mellitus with diabetic cataract
C104y00 Other specified diabetes mellitus with renal complications
C108C00 Insulin dependent diabetes mellitus with polyneuropathy
C10E312 Insulin dependent diabetes mellitus with multiple complicat
C109B00 Non-insulin dependent diabetes mellitus with polyneuropathy
C108300 Insulin dependent diabetes mellitus with multiple complicatn
C10yz00 Diabetes mellitus NOS with other specified manifestation
C109C12 Type 2 diabetes mellitus with nephropathy
C108711 Type I diabetes mellitus with retinopathy
C109E11 Type II diabetes mellitus with diabetic cataract
C108511 Type I diabetes mellitus with ulcer
C108600 Insulin dependent diabetes mellitus with gangrene
C10zy00 Other specified diabetes mellitus with unspecified comps
C109H12 Type 2 diabetes mellitus with neuropathic arthropathy
C10FA11 Type II diabetes mellitus with mononeuropathy
C10EH00 Type 1 diabetes mellitus with arthropathy
C109500 Non-insulin dependent diabetes mellitus with gangrene
C108712 Type 1 diabetes mellitus with retinopathy
C10F311 Type II diabetes mellitus with multiple complications
C109D00 Non-insulin dependent diabetes mellitus with hypoglyca coma
C109011 Type II diabetes mellitus with renal complications
C109300 Non-insulin-dependent diabetes mellitus with multiple comps
C10yy00 Other specified diabetes mellitus with other spec comps
C108y00 Other specified diabetes mellitus with multiple comps
C108200 Insulin-dependent diabetes mellitus with neurological comps
C10E600 Type 1 diabetes mellitus with gangrene
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C10FE11 Type II diabetes mellitus with diabetic cataract
C109012 Type 2 diabetes mellitus with renal complications
C102000 Diabetes mellitus, juvenile type, with hyperosmolar coma
C108F00 Insulin dependent diabetes mellitus with diabetic cataract
C109E12 Type 2 diabetes mellitus with diabetic cataract
C109H11 Type II diabetes mellitus with neuropathic arthropathy
C109511 Type II diabetes mellitus with gangrene
C10y100 Diabetes mellitus, adult, + other specified manifestation
C10z000 Diabetes mellitus, juvenile type, + unspecified complication
C102z00 Diabetes mellitus NOS with hyperosmolar coma
C103000 Diabetes mellitus, juvenile type, with ketoacidotic coma
C109D12 Type 2 diabetes mellitus with hypoglycaemic coma
C103z00 Diabetes mellitus NOS with ketoacidotic coma
C10EB00 Type 1 diabetes mellitus with mononeuropathy
C105000 Diabetes mellitus, juvenile type, + ophthalmic manifestation
C10E511 Type I diabetes mellitus with ulcer
C10E911 Type I diabetes mellitus maturity onset
C10E912 Insulin dependent diabetes maturity onset
C10FD11 Type II diabetes mellitus with hypoglycaemic coma
C10FC11 Type II diabetes mellitus with nephropathy
C108012 Type 1 diabetes mellitus with renal complications
C109G00 Non-insulin dependent diabetes mellitus with arthropathy
C109512 Type 2 diabetes mellitus with gangrene
C105y00 Other specified diabetes mellitus with ophthalmic complicatn
C10E411 Unstable type I diabetes mellitus
C108011 Type I diabetes mellitus with renal complications
C109C11 Type II diabetes mellitus with nephropathy
C10F411 Type II diabetes mellitus with ulcer
C10C.12 Maturity onset diabetes in youth type 1
C10E611 Type I diabetes mellitus with gangrene
C108F11 Type I diabetes mellitus with diabetic cataract
C10FB11 Type II diabetes mellitus with polyneuropathy
C10E412 Unstable insulin dependent diabetes mellitus
C109F11 Type II diabetes mellitus with peripheral angiopathy
C10F011 Type II diabetes mellitus with renal complications
C108212 Type 1 diabetes mellitus with neurological complications
C108D11 Type I diabetes mellitus with nephropathy
C10FM11 Type II diabetes mellitus with persistent microalbuminuria
C10E712 Insulin dependent diabetes mellitus with retinopathy
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C10E711 Type I diabetes mellitus with retinopathy
C108J12 Type 1 diabetes mellitus with neuropathic arthropathy
C109B11 Type II diabetes mellitus with polyneuropathy
C108411 Unstable type I diabetes mellitus
C108J11 Type I diabetes mellitus with neuropathic arthropathy
C108H00 Insulin dependent diabetes mellitus with arthropathy
C109211 Type II diabetes mellitus with neurological complications
C10E311 Type I diabetes mellitus with multiple complications
C10F111 Type II diabetes mellitus with ophthalmic complications
C108812 Type 1 diabetes mellitus - poor control
C109D11 Type II diabetes mellitus with hypoglycaemic coma
C109111 Type II diabetes mellitus with ophthalmic complications
C109F12 Type 2 diabetes mellitus with peripheral angiopathy
C10EA11 Type I diabetes mellitus without complication
C108z00 Unspecified diabetes mellitus with multiple complications
C103100 Diabetes mellitus, adult onset, with ketoacidotic coma
C107000 Diabetes mellitus, juvenile +peripheral circulatory disorder
C108E12 Type 1 diabetes mellitus with hypoglycaemic coma
C109A00 Non-insulin dependent diabetes mellitus with mononeuropathy
C10EG00 Type 1 diabetes mellitus with peripheral angiopathy
C108912 Type 1 diabetes mellitus maturity onset
C108412 Unstable type 1 diabetes mellitus
C10F211 Type II diabetes mellitus with neurological complications
C10EA12 Insulin-dependent diabetes without complication
Cyu2300 [X]Unspecified diabetes mellitus with renal complications
C10E012 Insulin-dependent diabetes mellitus with renal complications
C108B00 Insulin dependent diabetes mellitus with mononeuropathy
C108211 Type I diabetes mellitus with neurological complications
C109G12 Type 2 diabetes mellitus with arthropathy
C109A11 Type II diabetes mellitus with mononeuropathy
C108H11 Type I diabetes mellitus with arthropathy
C108911 Type I diabetes mellitus maturity onset
C10EN11 Type I diabetes mellitus with ketoacidotic coma
C109112 Type 2 diabetes mellitus with ophthalmic complications
C10EC11 Type I diabetes mellitus with polyneuropathy
C104000 Diabetes mellitus, juvenile type, with renal manifestation
C108A11 Type I diabetes mellitus without complication
C10EP11 Type I diabetes mellitus with exudative maculopathy
C10E112 Insulin-dependent diabetes mellitus with ophthalmic comps
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Read code Read term
C10E512 Insulin dependent diabetes mellitus with ulcer
C108B11 Type I diabetes mellitus with mononeuropathy
C10E111 Type I diabetes mellitus with ophthalmic complications
Kyu0300 [X]Glomerular disorders in diabetes mellitus
C10EE12 Insulin dependent diabetes mellitus with hypoglycaemic coma
C10EF12 Insulin dependent diabetes mellitus with diabetic cataract
C10EC12 Insulin dependent diabetes mellitus with polyneuropathy
C10E212 Insulin-dependent diabetes mellitus with neurological comps
C10ED12 Insulin dependent diabetes mellitus with nephropathy
C10EL11 Type I diabetes mellitus with persistent microalbuminuria
C108112 Type 1 diabetes mellitus with ophthalmic complications
C10FF11 Type II diabetes mellitus with peripheral angiopathy
C10F511 Type II diabetes mellitus with gangrene
History of immunosuppressive conditions at any point previous to the study consultation
43C3.11 HIV positive
A788.11 Human immunodeficiency virus infection
A788.00 Acquired immune deficiency syndrome
7840.00 Total excision of spleen
PK01.11 Asplenia
D415700 Splenic infarction
A788z00 Acquired human immunodeficiency virus infection syndrome NOS
PK0..00 Anomalies of spleen
PK01.00 Absent spleen
D415.00 Other diseases of spleen
D415z00 Disease of spleen NOS
A788000 Acute human immunodeficiency virus infection
A789000 HIV disease resulting in mycobacterial infection
8C31.00 Transplant immunosuppression
7840z00 Total excision of spleen NOS
A789400 HIV disease resulting in multiple infections
B905300 Neoplasm of uncertain behaviour of spleen
A789A00 HIV disease resulting in wasting syndrome
A789600 HIV disease resulting in Burkitt’s lymphoma
7841.00 Other excision of spleen
PK0z.00 Anomalies of spleen NOS
D415400 Splenic atrophy
A788y00 Human immunodeficiency virus with other clinical findings
A789700 HIV dis resulting in both types of non-Hodgkin’s lymphoma
A789900 HIV disease resulting in lymphoid interstitial pneumonitis
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Read code Read term
A788W00 HIV disease resulting in unspecified malignant neoplasm
A788200 HIV infection with persistent generalised lymphadenopathy
A789X00 HIV dis reslt/oth mal neopl/lymph,h’matopoetc+reltd tissu
A789100 HIV disease resulting in cytomegaloviral disease
A788500 Human immunodeficiency virus with secondary infection
A788400 Human immunodeficiency virus with neurological disease
A788300 Human immunodeficiency virus with constitutional disease
A788U00 HIV disease result/haematological+immunologic abnorms,NEC
A788X00 HIV disease resulting/unspcf infectious+parasitic disease
D415600 Splenic fibrosis
AyuC600 [X]HIV disease resulting in other non-Hodgkin’s lymphoma
AyuCB00 [X]HIV disease result/haematological+immunologic abnorms,NEC
AyuC300 [X]HIV disease resulting in multiple infections
AyuCC00 [X]HIV disease resulting in other specified conditions
AyuC400 [X]HIV disease resulting/other infectious+parasitic diseases
A789800 HIV disease resulting in multiple malignant neoplasms
AyuCD00 [X]Unspecified human immunodeficiency virus [HIV] disease
A788600 Human immunodeficiency virus with secondary cancers
B62y700 Malignant lymphoma NOS of spleen
B1z1.00 Malignant neoplasm of spleen NEC
History of immunosuppressive therapy in the year previous to the study consultation
8BAD.00 Chemotherapy
8BA5.00 Oral chemotherapy
7L16100 Intravenous chemotherapy
8BAD000 Cancer chemotherapy
7L18200 Intramuscular chemotherapy
7L1d.00 Delivery of chemotherapy for neoplasm
8BAL.00 Combined pre-operative chemotherapy and radiotherapy
7L1dz00 Delivery of chemotherapy for neoplasm NOS
7L1e.00 Delivery of oral chemotherapy for neoplasm
7L1ez00 Delivery of oral chemotherapy for neoplasm NOS
7L1dy00 Other specified delivery of chemotherapy for neoplasm
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Appendix 6 FLU-CATs Data Handbook
Data sets
Data for the Flu-CATs Study are collected and uploaded on a weekly and on a monthly basis on to
Dropbox by Emma Boyle from CPRD. Each week, two data sets are saved on to Dropbox: one each
for children and adults. The following naming convention is followed for the weekly data sets:
adults_YYYYMMDD and child_YYYYMMDD, with the date of the Monday for each week, for adult and
children data sets, respectively.
Each monthly upload comprises four data sets: one data set each with LEPIS form data for adults and
children (named form_adults_YYYY_MM and form_child_YYYY_MM); one ‘master file’ (named
masterfile_YYYY_MM) containing data on comorbidities, selected treatments and vaccinations; and one
‘patient file’ (named patient_YYYY_MM) containing data that includes dates of death and transfer-out dates.
The weekly data sets are uploaded as tab-delimited text files on to Dropbox and the monthly data sets are
saved as Stata files. Detailed data dictionaries for each of the weekly and monthly data sets are provided
in the appendix.
‘Do files’
Data management Some data management is necessary for the weekly data sets before they can be
analysed. The weekly data sets are saved as text files. They will first need to be downloaded off Dropbox
and then ‘insheeted’ into Stata so as to convert them into Stata format. Once this is done, the relevant
data management ‘do file‘ will need to be run.
Separate data management ‘do files’ have been prepared for adults and children. Each of the ‘do files’ is
to be opened in Stata after the weekly FLU-CATs file has been ‘insheeted’ into Stata. Once ‘insheeted’,
the ‘do file‘ may be executed and this should result in a complete run of the ‘do file’ with no errors. The
resulting ‘clean’ file may then be saved as a Stata file. The ‘clean’ weekly data files will contain clinical
measurements and other data collected through the LEPIS form in addition to each of the seven
CATs criteria.
The monthly Flu-CATs data uploads require some minimal data management, which is included in the
automation do file. The monthly data uploads do not require any additional data management.
The automation and analysis ‘do files’ may be run directly on the files downloaded off Dropbox.
PMEWS and CATs A separate ‘do file’ has been written to calculate PMEWS scores in adults. Although the
physiological data (MEWS) component can be carried out, using the weekly data downloads, to score
the patient data, merging with the monthly data downloads from CPRD will be required as comorbidity
data and patient age data are needed. The PMEWS ‘do file’ performs the necessary data management and
generates cumulative PMEWS and CATs scores for the data set.
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Data reports
‘Do files’ have been written to generate weekly and monthly FLU-CATs data reports. Separate ‘do files’
have been written for adult data and children data, although they are both identical except for the three
variables that are present only in the adult data set (blood pressure, social isolation and performance status).
Weekly reports
For weekly reports, the ‘clean’ weekly Stata file is to be used. The input and output directories will need
to be checked and modified if necessary. Once this has been done, the ‘do file’ may be executed. This
should result in a complete run with no errors and a new Excel spreadsheet (titled ‘Results.xls’) with the
weekly report should be created in the specified output folder. It is recommended that the results Excel
spreadsheet is copied and re-saved in a different directory before running the next set of analyses, as these
the ‘do files’ are programmed to overwrite the existing results spreadsheet.
At the time of writing this handbook, the latest tranche of weekly data for children (uploaded on
27 April 2015) does not have sufficient observations for outcome #1– ‘decision to treat with antivirals’ to
obtain ORs, unadjusted or adjusted, for association with each of the CATs criteria. Because of this, the
automated weekly report ‘do file’ terminates at this point. Until sufficient numbers for this outcome are
obtained, the following is recommended:
i. Run the ‘do file’ until the error message is seen (until Outcome #1).
ii. At this point, select portions of the ‘do file’ from Outcome #2 onwards and execute.
Monthly reports
From the monthly tranche of FLU-CATs data, the ‘master file’ and the ‘patient file’ will be used to generate
a word document summarising findings for each month. As with the weekly data report ‘do files’, the
directories with have to be checked and modified if necessary. Once this has been done, the ‘do file’ may
be executed. This should result in a complete run with no errors and a new Word document (titled
‘mydoc1.rtf’) with the monthly report should be created in the specified output folder.
Notes
l The monthly report ‘do file’ is best run in new Stata program window. If any changes are made to the
‘do file’ midway through executing the ‘do file’, save the changes (as a separate ‘do file’, if needed),
close Stata and reopen the ‘do file’ in a new Stata window.
l The monthly report document (opens in Word) will need to have all of the plots (saved as
‘myplot1.eps’, ‘myplot2.eps’, and so on) presented within the document to be saved in the same folder
as the monthly report document itself. This must be kept in mind while e-mailing or sharing monthly
reports– all plot files will have to be shared along with the report itself.
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Data set descriptions
Weekly data set: adult (as provided by Clinical Practice Research Datalink)
Variable name Type Description
patid long Unique patient identifier
pracid int Unique practice identifier
formid int Unique LEPIS form identifier
submit_date long Date of submission of FLU-CATs form (assumed to be the date of
FLU-CATs consultation)
cat str5 Category: adults/children (all adults in this data set)
gender byte Gender: male or female
birthyear int Patient’s year of birth
mob byte Patient’s month of birth (for those aged under 16). 0 indicates no
month set
frddate str10 Date the patient first registered with the practice
regdate str10
utsdate str10 Date at which the practice data is deemed to be of research quality
todate str10 Date the patient transferred out of the practice, if relevant. Empty
for patients who have not transferred out
toreason byte Reason the patient transferred out of the practice
deathdate str10 Date of death of patient
lcdate str10 Date of the last collection for the practice
accept byte Flag to indicate whether the patient has met certain quality
standards: 1= acceptable, 0= unacceptable
temperature str32 Body temperature: measured/not measured
temperaturevalue str4 Body temperature value in °C
severerespiratorydistress str3 Severe respiratory distress– yes/no
respiratoryexhaustion str3 Respiratory exhaustion: yes/no
respiratoryrate str32 Respiratory rate: measured/not measured
respiratoryratevalue str2 Respiratory rate value in breaths per minute
patientonoxygen str3 Is the patient on oxygen? yes/no
patientonoxygenvalue str2 Is this oxygen need new and related to this episode? yes/no
peripheraloxygensaturation str30 Peripheral oxygen saturation: measured/not measured
peripheraloxygensaturationvalue str3 Peripheral oxygen saturation value (%)
heartrate str32 Heart rate: measured/not measured
heartratevalue str3 Numerical heart rate value
bloodpressure str12 Blood pressure: measured/not measured
bloodpressuresystolic str3 Systolic blood pressure value (mmHg)
bloodpressurediastolic str3 Diastolic blood pressure value (mmHg)
capillaryrefilltime str40 Capillary refill time: measured/not measured
severedehydration str2 Signs of severe dehydration: yes/no
newalteredconsciouslevel str21 New altered consciousness level: alert/confused or agitated/
response to voice only/response to pain only
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Variable name Type Description
socialisolation str7 Lives alone or no fixed abode: yes/no/unknown
performancestatus str48 Patient’s usual activity and ability to self-care prior to this
acute illness
causingotherclinicalconcern str3 Causing other clinical concern? yes/no
causingotherclinicalconcernvalue str150 Description of the clinical concern (≤ 150 characters)
treatwithantivirals str3 Decision to treat with antivirals: yes/no
treatwithantibiotics str3 Decision to treat with antibiotics: yes/no
refertohospital str3 Decision to refer to hospital: yes/no
Weekly data set: children (as provided by Clinical Practice Research Datalink)
Variable name Type Description
patid long Unique patient identifier
pracid int Unique practice identifier
formid int Unique LEPIS form identifier
submit_date long Date of submission of Flu-CATs form (assumed to be the date of
Flu-CATs consultation)
cat str5 Category: adults/children (all children in this data set)
gender byte Gender: male of female
birthyear int Patient’s year of birth
mob byte Patient’s month of birth (for those aged under 16). 0 indicates no
month set
frddate str10 Date the patient first registered with the practice
regdate str10
utsdate str10 Date at which the practice data is deemed to be of research quality
todate str10 Date the patient transferred out of the practice, if relevant. Empty
for patients who have not transferred out
toreason byte Reason the patient transferred out of the practice
deathdate str10 Date of death of patient
lcdate str10 Date of the last collection for the practice
accept byte Flag to indicate whether the patient has met certain quality
standards: 1= acceptable, 0= unacceptable
temperature str32 Body temperature: measured/not measured
temperaturevalue str4 Body temperature value in °C
severerespiratorydistress str3 Severe respiratory distress: yes/no
respiratoryexhaustion str3 Respiratory exhaustion: yes/no
respiratoryrate str32 Respiratory rate: measured/not measured
respiratoryratevalue str2 Respiratory rate value in breaths per minute
patientonoxygen str3 Is the patient on oxygen? yes/no
patientonoxygenvalue str2 Is this oxygen need new and related to this episode? yes/no
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Variable name Type Description
peripheraloxygensaturation str30 Peripheral oxygen saturation: measured/not measured
peripheraloxygensaturationvalue str3 Peripheral oxygen saturation value (%)
heartrate str32 Heart rate: measured/not measured
heartratevalue str3 Numerical heart rate value
capillaryrefilltime str40 Capillary refill time: measured/not measured
severedehydration str2 Signs of severe dehydration: yes/no
newalteredconsciouslevel str21 New altered consciousness level: alert/confused or agitated/
response to voice only/response to pain only
causingotherclinicalconcern str3 Causing other clinical concern? yes/no
causingotherclinicalconcernvalue str150 Description of the clinical concern (≤ 150 characters)
treatwithantivirals str3 Decision to treat with antivirals: yes/no
treatwithantibiotics str3 Decision to treat with antibiotics: yes/no
refertohospital str3 Decision to refer to hospital: yes/no
Monthly data sets
Four data sets are uploaded on to Dropbox by CPRD each month: two form data sets (one each for adults
and children), one master file and 1 patient file. The two form files contain cumulative data from 4 weeks
in one ‘monthly’ data set each for adults and children. The variables in the form files are identical to the
variables in the respective weekly data extracts. Descriptions for the master file and the patient file are
given below.
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Master file
Variable name Type Description
patid long Unique patient identifier
cat str5 Category: Adults/Children
cardiovascular float Presence of cardiovascular disease: yes/no
liver float Presence of liver disease: yes/no
neurological float Presence of neurological disease: yes/no
renal float Presence of renal disease: yes/no
respiratory float Presence of respiratory disease: yes/no
diabetes float Presence of diabetes: yes/no
immune_supression float Presence of immunosuppression: yes/no
statin float Prescription of statins: yes/no
antibiotic float Prescription of antibiotics: yes/no
antiviral float Prescription of antivirals: yes/no
flu_vaccination float Seasonal influenza vaccination: yes/no
hib float Haemophilus influenza type B vaccination: yes/no
inhaled_steroids float Prescription of steroids (inhaled): yes/no
oral_steroids float Prescription of steroids (oral): yes/no
pneumococcal_vaccine float Pneumococcal vaccination: yes/no
Comorbidities and therapy variables have been coded as ‘Yes’ for presence of the relevant medcodes/prodcodes at any
point before the FLU-CATs consultation.
Patient file
Variable name Type Description
patid long Unique patient identifier
pracid int Unique practice identifier
cat str5 Category: adults/children
formid int Unique LEPIS form identifier
submit_date float Date of submission of FLU-CATs form (assumed to be the date of
FLU-CATs consultation)
gender byte Gender: male of female
yob int Patient’s year of birth (Stata date format)
mob byte Patient’s month of birth
toreason byte Reason the patient transferred out of the practice
year float Patient’s year of birth (YYYY format)
regdate float
todate float Date the patient transferred out of the practice, if relevant. Empty
for patients who have not transferred out
death float Date of death if the patient died
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Appendix 7 FLU-CATs protocol
NIHR Second Pandemic Influenza Themed Call: Detailed
Project Description
Long Title: Real time refinement and validation of criteria and tools used in primary care to aid hospital
referral decisions for patients of all ages in the event of surge during an influenza pandemic.
Short Title: Evaluation and refinement of pandemic influenza community assessment tools
(the FLU-CATs study)
MG Semple, JS Nguyen Van Tam, PR Myles, JJ Kirkham, TJ Williams, TP van Staa
Summary
Design: A prospective analysis, linking criteria in a GP’s assessment of patients presenting with influenza
like illness, to immediate management decisions and patient outcomes.
Objective: Assessment, refinement and validation of triage tools to guide GP referral of patients with
influenza like illness during a pandemic in readiness for use should widespread illness exceed health care
capacity (surge).
Method: GPs participating in the General Practice Research Database (GPRD) will record their assessment
and management of patients with influenza like illness in LEPIS (Local Eligibility Patient Identification
Service) an application linked to their routine in-practice software (Vision®). This is an established
information technology based method for conducting large research studies in primary care.
High level hospital discharge data are routinely uploaded from secondary care to Vision® including:
admission date, discharge date, main disease code, main procedure code and if death in hospital date of
that death.
There is automated nightly linkage from Vision® and LEPIS to GPRD. This is collated by the GPRD research
operations team and made available to external researchers on a weekly basis.
GPRD is linked to detailed Hospital Episode Summary data every three months. Data linked includes
multiple disease codes, multiple procedure codes, length of admission, levels of augmented care (0 to 3),
mortality, and pharmacoeconomics.
Analysis: Weekly cumulative analyses are planned using GPRD data. Three monthly analyses are planned
using linked HES data as a gold standard.
Univariate and multivariate analyses using unconditional logistic regression will be used to investigate the
association between triage criteria threshold values and primary outcomes (hospital admission, and death)
and secondary outcomes (length of stay and augmented levels of care [high dependency/intensive care]).
The threshold values of triage criteria will be refined by comparing the receiver operator characteristics at
various thresholds of abnormality (e.g. respiratory rate of > 30, > 35, > 40).
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The discriminatory value of existing and refined triage tools will be compared using logistic regression.
Triage tools will be compared for their ability to predict outcomes using Area Under the Receiver Operating
Characteristic Curve (AUROC) comparisons. The sensitivity, specificity, positive predictive value (PPV) and
negative predictive value (NPV) will be calculated for triage tools using different score thresholds.
The virus, human behaviour, and models of health care provision in the community may change in time.
Analysis will be reset between pandemic waves and appropriate comparisons made between
pandemic waves.
Protocol amendment
The Award Board asked the investigators to consider add an extra resource to include virological diagnosis
in a sub sample of patients.
We will explore linking GPRD to the HPA supra-regional microbiology network database to provide
linked-anonymised results on microbiological investigations for respiratory pathogens. This will still require
NIGB approval and Caldicott compliance. Preliminary enquiries have discovered that a supra-regional
database is used by several of the nine HPA regions. This includes patient linked data on communicable
diseases including the HPA/RCGP influenza virus swab results. GPRD is now linked to ten NHS datasets
(including Hospital Episode Statistics, death certificates, cancer registry data, data from the Myocardial
Infraction National Audit Program [MINAP]). These linkages are done on a regular basis using a Trusted
Third Party and are all subject to NIGB approval. The project submitted involves already established links
between GPRD, HES and Death Certifications. Establishing linkage to the HPA data-set would be a
significant additional task for the study but one that would bring great benefit and avoid need for
additional swabs to be taken.
Further details of protocol amendments including revised costs to resource linkage to the HPA are given at
the end of this document.
Timeline
Phase one: (inter-pandemic – development / feasibility testing), duration six months during a summer
season: set-up and validation of processes; optimisation of the clinical record entry screen; GP acceptability
testing; establish data-return format; check completeness of data returns; develop data clean-up
algorithms; development of definitions, evaluation of completeness and validation of study outcomes using
historical GPRD and HES data; test of LEPIS study link. This will involve 3 to 5 practices experienced in
developing GPRD/LEPIS research protocols.
Phase two: (inter-pandemic – pilot), duration six months in the consecutive winter season in 50 practices.
Using data from cases of influenza like illness: test data-cleaning algorithms and the automated weekly
evaluation of performance of triage criteria and tools. Rehearse report preparation to match expected
‘battle rhythm’ of key pandemic policy advisory bodies (SAGE and PICO). The project will be mothballed at
end of phase two.
Phase three: will be activated in the event of a pandemic. The study link to LEPIS will be embedded in
the Vision® software at all GPRD practices (currently 629) by the routine update process. GPs will be will
prompted to complete assessment and outcome fields for cases presenting with influenza like illness. The
GPRD research group will provide weekly data returns for these patients and three monthly linked HES
data. We will run a weekly cumulative analysis against primary outcomes, allowing frequent refinement of
criteria and tools against the novel pandemic strain, three monthly validation against HES data and plan
adaptation of tools in readiness of surge.
An outline of the study as it would run in phases two and three is presented on page 20.
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Has the project changed since the Expression of Interest was submitted? Yes
The title has changed to reflect that the aim of the study is to prospectively refine and validate the triage
tools in real-time ready for use in the event of surge.
We have added Dr Jamie Kirkham, Centre for Medical Statistics and Health Evaluation, University of
Liverpool, as a co-investigator to provide methodological and statistical support to the study at 3% WTE.
We have added a full time pre-doctoral research assistant based at the University of Nottingham to
conduct statistical scripting and run analysis in year one. In lieu of this substantial change and additional
salary costs, University of Nottingham have agreed to make a 100% institutional contribution to their
estates and indirect costs.
Introduction
The potential for health care demand to exceed clinical capacity (surge) is recognised in historic reports of
influenza pandemics and current government guidance.[1,2] Clinical triage tools capable of identifying the
need for higher levels of care and risk of severe outcome have an important role in pandemic situations
where secondary care capacity may be insufficient to meet demand; the time available for clinical decision
making may be limited by workload pressures; and healthcare workers unfamiliar with clinical assessment
and admission decision making may be asked to fulfil ‘gatekeeper’ roles.[3]
CURB-65 is a validated predictor of mortality from community acquired pneumonia in adults but was never
intended for use in children.[4,5] CURB-65 does not perform as well in predicting higher levels of care and
was not designed to predict mortality from non-pneumonic presentations.[6,7] Challen et al. proposed
the Pandemic Medical Early Warning Score (PMEWS) as a clinical triage tool to aid hospital admission
decisions for adults in a pandemic situation.[8] They validated PMEWS in adults presenting to hospital with
community acquired pneumonia and found that it was better than CURB-65 for predicting the need for
admission and higher levels of care but had limited ability to predict mortality. CURB-65 and PMEWS pose
problems for use in primary care, the first being in-part reliant upon a contemporaneous serum urea value
and the second is computationally complicated. Other severity scoring tools exist but these are not suitable
for use in primary care due to a greater dependence upon laboratory or radiological investigations.
In 2009, the Department of Health England published a package of care that included Paediatric and Adult
Community Assessment Tools (CATs) and patient pathways for use by the NHS in a severe pandemic event.[9]
CATS were developed to help non-specialist front-line staff identify which sick children and adults are most
likely to benefit from interventions and levels of care only available in hospitals when resources are limited.
CATs were developed by paediatric and adult expert clinical development groups drawing on evidence that
supports the recognition of severe influenza and severe pneumonia in the community in adults and children in
resource limited settings; severe chronic obstructive pulmonary disease in adults; potentially serious feverish
illness in children; and severe bronchiolitis in infants.[3,10,11,12,13,14,15,16,17,18,19] Clinicians were
warned not to use the CATs and the pathways unless the local situation precluded normal admission and
discharge processes.
CATs use six objective and one subjective criteria based on simple clinical assessment (figure 1). Meeting
any CAT criterion warrants referral and admission to hospital. Criteria are: A) severe respiratory distress, B)
increased respiratory rate, C) oxygen saturation > 2% on pulse oximetry breathing air or oxygen, D)
respiratory exhaustion, E) severe dehydration or shock, F) altered consciousness level and G) other clinical
concern. While criteria fields are common to adult and paediatric CATs, the abnormal physiological
thresholds and clinical signs are age appropriate. Like PMEWS, there is no requirement for laboratory
investigation to complete the assessment. However CATs were only intended for use ‘during severe and
exceptional circumstances when surge demand for healthcare services leads to a need for strict triage”;
and as such, were not deployed during the 2009/10 pandemic.
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Work underpinning this study
Goodacre and colleagues (2010) conducted an evaluation of the discriminatory value of the CURB-65
score, PMEWS and CATs for predicting severe illness or mortality in patients with suspected pandemic
influenza, but were unable to draw any conclusions regarding their clinical utility in a pandemic situation
due to insufficient case numbers especially of adults, and a low incidence of severe outcome.[20]
Semple, Myles, Van-Tam and other members of the UK Pandemic Influenza Clinical Information Network
(FLU-CIN) characterised PCR-confirmed pandemic influenza disease in a much larger cohort of 1520 people
(1040 adults, 480 children (age < 16 years)) admitted to hospital.[21] (Thorax submitted) FLU-CIN compared
the clinical validity and utility of CATs, PMEWS and CURB-65 as predictors for interventions normally
only available in hospital, higher levels of care, and death using area under the Receiver Operating
Characteristic (ROC) curve (AUROC) comparisons with 95% confidence intervals (paper submitted).[22] CATs
showed the best predictive performance for level 2/3 admissions in both adults [AUROC: CAT 0.77 (0.73,
0.80); CURB-65 0.68 (0.64, 0.72); PMEWS 0.68 (0.64, 0.73), comparison of AUROCs p<0.001] and children
[AUROC: CAT 0.74 (0.68, 0.80); CURB-65 0.52 (0.46, 0.59); PMEWS 0.69 (0.62, 0.75), p< 0.001].
While the FLU-CIN cohort is limited to patients admitted to hospital with severe influenza and its
complications, the data show that triage tools are capable of predicting higher levels or care and or death
in children and adults. However the FLU-CIN analysis does not include assessment of triage tools in
primary care.
Appropriate use of such triage tools in the community could expedite referral to hospital and where scores
are high, immediate admission to level 2/3 care. Prompt admission and allocation of higher levels of care
may be associated with improved patient outcomes. Another study by FLU-CIN found that delayed
admission to hospital (≥ 4 days after symptom onset) was significantly associated with increased likelihood
of admission to critical care and death.[23]
The validity and utility of using triage tools in the community remains untested. Morbidity and mortality
rates were low during the H1N1(2009) event when compared to some previous influenza epidemics such
as the one in 1989/90 [24] and the use of anti-viral therapy was generally low in the FLU-CIN cohort
despite it being widely available at the time. A more severe pandemic may be associated with a greater
acceptance of anti-viral therapy and this may impact upon need for higher levels of care and death.
Consequently criteria threshold values may need to be adjusted to optimize the ROC for each criterion and
the AUROCs for the various triage tools.
Justification of this study
The validity and utility of the various triage tools needs to be assessed in a large community-based
prospective study of patients presenting with influenza like illness to General Practitioners (GPs), to give
confidence to clinicians who make be asked to use such tools in the event of surge, and policy makers
who may need to recommend their use to GPs.
Linking GP assessment and management decisions to hospital episode data enables assessment and
comparison of the validity and utility of triage in the community in relation to patient relevant outcomes
(hospital admission, length of stay, higher levels of care and death).
It would not be possible to conduct this study during a pandemic without prior development of processes,
feasibility and pilot studies.
The Health Protection Agency timeline for the UK 2009 pandemic shows only 12 weeks between
identification of person-to-person transmission in the UK (first week May) and peak influenza activity
(last week July) in the first pandemic wave. Prospective data collection with near real-time iterative and
cumulative analysis is the only method for validating triage criteria and tools against a novel pathogen in
such a short time.
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Since pandemics are unpredictable and infrequent, limited but potentially useful information will be gained
from prospective feasibility and pilot work conducted in primary care during seasonal influenza while
H1N1v is still circulating.
Conducting this study in real-time during the early stages of a pandemic, when the characteristics of the
novel virus are not fully understood, is important as it allows refinement and validation of triage tools
against the novel pathogen in preparation for possible surge. This cannot be done until a novel virus
emerges. Dame Diedre Hine has recommended that population based studies be established that,
in the early stages of a future pandemic, can measure the severity of the pandemic and support
decision making.[25]
The study method adheres to the five principles of Dynamic Risk Assessment and as applied to the
management of emergency situations by UK Government agencies (Evaluate, Select, Assess, Refine,
Reassess) (Home Office Guide to Operational Risk Assessment - Generic Risk Assessment 3.2. [Version 2
September 2008]).
If, as in the 1918/19 epidemic, the behaviour of the virus is markedly different in terms of severity between
the first and subsequent waves or evolves to cause severe disease in a particular organ system; then triage
criteria may need to be adapted to reflect the consequent changes in health care demand and
clinical presentation.
Research objectives
Aim
To establish processes now, that can be used in the early stages of a future pandemic event to provide
valid community triage tools capable of assisting hospital referral decisions for people of all ages for use if
health care demands exceed health care capacity (surge).
Primary objective
From the start of a future pandemic event, to describe on a weekly cumulative basis the association
between various triage tools and pandemic influenza outcomes. This will be supplemented as appropriate,
with receiver operator characteristic (ROC) curves analysis and predictive values (positive and negative) of
various community triage tools (Adult and Paediatric CATs, PMEWS) to predict outcomes (hospital
admission and or death) in people of all ages presenting with pandemic influenza like illness to a large
number of general practices in the UK; and to feed this information back to policy makers via the
Pandemic Influenza Clinical and Operational Advisory Group’s Clinical Sub-group (PICO) and medical
members of the Scientific Advisory Group for Emergencies (SAGE).
Secondary objectives
1. To provide reassurance that it is safe for people who do meet triage criteria and so would not be
referred for hospital admission to continue to be managed in the community with advice.
2. To describe the associations between specific triage criteria and outcomes (hospital admission, length of
stay, need for higher levels of care and or death).
3. Using sensitivity analysis to refine threshold values for specific triage criteria and outcomes (hospital
admission, length of stay, need for higher levels of care and or death).
4. To describe demographics and clinical features of patients that meet threshold criteria and are referred
for admission by GPs but are declined admission on assessment at hospital.
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5. To describe demographics and clinical features of patients that present with influenza like illness to GPs
and after assessment are not considered to need referral to hospital, yet die in the community within
30 days.
6. To describe demographics and clinical features of patients that present with influenza like illness to GPs
and after assessment are not considered to need referral to hospital, yet die in hospital within 30 days.
We will analyse:
1. separately by age group: adults and children (< 16 years)
2. cumulatively for primary objectives.
3. weekly for primary objectives from initiation of study.
4. three monthly for secondary objectives.
Policy related
To provide evidence and reassurance to clinicians, policy makers and Ministers that any triage tools
recommend for use in the event of surge are validated against the novel pathogen, are safe to use and
clinically justified.
Plan of study
The study will run in three phases:
l Phase one (inter-pandemic – development and feasibility). Proposed start date 01.04.2012. Duration
six months during a summer season. At the start of this project, the researchers will evaluate in detail
the validity and completeness of recording of the outcome measures in GPRD (analysing the data as
collected up to the start of the study). Code lists will be developed. The frequency of recording of
various data fields will be evaluated. In addition, comparisons will be made with HES in order to assess
the completeness of recording of hospital admissions. These analyses will provide important
information about the quality of GP recording of the outcomes. Based on the large number of
published validation studies with GPRD, it is expected that major clinical outcomes are generally
recorded well by GPs but that clinical details (such as length of hospital stay) may be less complete.
We will set-up and test the technology processes. This will involve 3 to 5 GP practices experienced in
developing GPRD research protocols GPs will be involved in optimising the study record entry screen in
LEPIS and do user acceptability testing. We will establish the data-return formats; check completeness
of data recording by GPs in LEPIS; develop data clean-up algorithms; development of definitions,
evaluation of completeness and validation of study outcomes using historical GPRD and HES data; test
LEPIS study link.
There will be meetings with the oversight committee prior to commencement, at mid point and end of
phase one.
l Phase two (inter-pandemic – pilot), Proposed start date 01.10.2012. Duration six months in the
consecutive winter season in 50 practices. Using data from cases of influenza like illness: test
data-cleaning algorithms and the automated weekly evaluation of performance of triage criteria and
tools. We will rehearse report preparation to match expected “battle rhythm” of key pandemic
advisory bodies (SAGE and PICO). There will be meetings with the oversight committee prior to
commencement, at mid point and end of phase two. The project will be mothballed at end of
phase two.
l Phase three will be activated in the event of a pandemic. The link to the web-based electronic record
(LEPIS) will be embedded in the Vision® software at all GPRD practices (currently 629) by the routine
update process. GPs will be will prompted to complete assessment and management fields for all cases
presenting with influenza like illness. The GPRD research group will provide weekly data returns for
these patients and three monthly linked hospital episode summary data. We will run a weekly
cumulative analysis against outcomes, allowing frequent refinement of criteria and tools against the
novel pandemic strain, and plan adaptation for use in readiness of surge.
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In the event of imminent surge, and at the direction of policy makers at devolved Departments of Health,
it will be possible to embed an algorithm behind the clinical record page in Vision®/LEPIS that will indicate
that triage criteria have been met and so prompt the GP to consider hospital referral. Regional variations of
Vision® software are provided to practices in devolved UK administrations, which will allow for variations in
regional policy. A decision by one administration not to use triage tools during surge would be respected
by not deploying the algorithm in that region. Because the GPRD is conducted in collaboration with the
providers of the Vision® in-practice software, it would be possible to link all users of Vision® software to
the algorithm, not just those participating in GPRD. We will explore the capability to provide and apply the
algorithm to other providers of GP software. The study will continue during surge. The study will continue
during surge. The triage algorithm will be removed when surge has ceased, and the study will continue.
Existing research
There have been two head to head comparisons of the triage tools proposed by DH guidance, both in
cohort of patients already admitted to hospital.[20,22]
The validity and utility of using PMEWs, CATs (both triage tools) and CURB-65 (a validated predictor of
mortality from community acquired pneumonia) to predict augmented levels of care and or death has
been studied by the FLU-CIN in 1520 patients admitted to hospital with confirmed pandemic influenza A
(H1N1)2009[22].
The ROC curves and AUROC values comparing the predictive value of the three clinical triage tools are
described in figure 2. CATs showed the best predictive performance for augmented higher levels of care
(effectively HDU and ITU admissions) in both adults [AUROC: CAT 0.77 (0.73, 0.80); CURB-65 0.68 (0.64,
0.72); PMEWS 0.68 (0.64, 0.73), comparison of AUROCs p< 0.001] and children [AUROC: CAT 0.74
(0.68, 0.80); CURB-65 0.52 (0.46, 0.59); PMEWS 0.69 (0.62, 0.75), p< 0.001]. CURB-65 and CAT had
similar performance in predicting mortality in adults [AUROC: CAT 0.70 (0.63, 0.77); CURB-65 0.71
(0.65, 0.77); PME 5WS 0.60 (0.52, 0.67), p= 0.009] but CAT performed best as a predictor of mortality
in children [AUROC: CAT 0.76 (0.66, 0.86); CURB-65 0.51 (0.39, 0.63); PMEWS 0.69 (0.55, 0.83), p= 0.002].
The receiver operator characteristic, sensitivity, specificity, positive predictive value (PPV) and negative
predictive value (NPV) were calculated for each of the tools using various score thresholds (table 1). In
adults, a CAT score ≥ 3 was the best predictor of level 2/3 admissions, death and combined severe
outcome when compared to various cut-off scores for either CURB-65 or PMEWS. In children, a CAT score
≥ 3 was the best predictor of level 2/3 admission and combined severe outcome; performing marginally
better than a PMEWS score > 9, both significantly better than CURB-65. In children, a PMEWS score > 9
was the best predictor of mortality in children; performing marginally better than a CAT score > 3, both
significantly better than CURB-65.
Anonymised electronic general practice data has been used extensively across a wide spectrum of disease
areas including seasonal and pandemic influenza. Watkins et al. used GPRD to determine the burden of
seasonal influenza in childhood.[26] Hansell et al. (1999) investigated the epidemiology of respiratory
disorders adopting similar methods.[27] Mangtani et al. (2004) investigated the effectiveness of influenza
vaccination in the elderly.[28] Time series analysis of a similar nature to this proposed study was undertaken
by Hajat et al. (1999) to determine the relationship between pollution and consultations for asthma and
lower respiratory disorders.[29][30]
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Research methods
Study design
Prospective observational maximum capture study using anonymised electronic general practice data linked
to extended hospital episode summary data.
It is important to note that there will be no specific interventions made by the study.
None of the clinical features that constitute triage criteria are novel.
All clinical feature of interest are examined albeit with variations of adherence in current
community practise.
Recruitment population
Any person presenting to a GPRD participating practice for consultation with a General Practitioner or
Primary Care Nurse Practitioner regardless of date of onset of disease and prior medical history.
GPs participating in GPRD are committed to improving the health of their communities by providing
anonymised data for a number of research and quality of service audit purposes.
Data collection templates with reminder flags are regularly uploaded to LEPIS and linked to Vision®
in-practice software for such purposes.
Inclusion criteria
Any person presenting to a GPRD participating practice with influenza like illness regardless of date of
onset of disease and prior medical history.
Exclusion criteria
People who present with any condition other than influenza like illness.
Proposed sample size
A formal sample size calculation is not possible and will depend to a great extent upon the clinical attack
rate and hospitalisation rate (severity) of the pandemic strain. The clinical attack rate and hospitalisation
rate of a future pandemic strain cannot be guessed, however the recent ‘mild’ pandemic does provide
useful information.
In the first wave of the 2009 pandemic the clinical attack rate varied considerably between regions from
446 cases per 100,000 in the rural South-West to 1344 cases per 100,000 in London.[31] Most people
experienced a mild, typical influenza like illness and the overall rate of hospitalisation ranged from 1.3% to
2.5% of those affected.
In the event of a pandemic and activation of phase 3 of the study, the study will recruit from all 629 practices
participating in the GPRD currently actively caring for approximately 5.14 million people. Based on the limits
of the clinical attack rates during the 2009 event, between 23,000 and 69,000 of these people would be
expected to present in the first wave. Approximately 10,000 to 30,000 of these patients will present in the
first 3 months before peak activity; forming the study cohort available for assessing, refining and validating
triage tools in preparation for surge. Based on the limits of the hospitalisation rates previous described,
130 to 750 of these people would be admitted to hospital forming the group with a positive primary
outcome measure in this study. In comparison, the FLU-CIN study was able to validate triage tools using
similar method of analyses in a cohort of 1520 patients admitted to hospital where the positive primary
outcomes groups comprised 250 (16.5%) people who required higher levels of care (level 2 HDU or 3 ITU)
and 80 (5.3%) who died. Thus we are confident that this study will be sufficiently powered to assess, refine
and validate the triage tools in the timetable described.
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Data Sources: The General Practise Research Database (GPRD) and linked
Hospital Episode data
The GPRD research group are named co-investigators in this application.
The General Practice Research Database (GPRD) is the world’s largest database of anonymised
longitudinal medical records from primary care. The Secretary of State for Heath has owned the database
since 1994. The GPRD is managed by Medicines and Healthcare products Regulatory Agency (MHRA).
The database comprises near real-time comprehensive observational data from over 1000 GPs working in
629 general practices. It is a valuable tool for academic research in a broad range of areas including clinical
epidemiology, disease patterns, disease management, outcomes research, and drug utilisation. The quality
and reputation of the GPRD data make it an invaluable resource for researchers. There have been over
890 research papers published in peer-reviewed journals using data from this database. In July 2011 data
was being collected on 5.14 million active patients of research standard or 8.3% of the UK population
attending. The GPRD closely reflects the age, gender, and geographic distribution of the UK.[32] The quality
of GPRD data has recently been reported in a systematic review. [33] While some acute musculoskeletal
and metabolic conditions are not well recorded in GPRD, the majority of diagnoses were reliably coded and
there is good agreement between more common diseases and other datasets. Importantly fro this study,
influenza incidence rates derived from GPRD agree closely with data from national influenza
surveillance systems.[30]
Detailed Hospital Episode Summary (HES) data is linked to GPRD every three months. HES data includes:
detailed disease codes (ICD-10), procedure codes, levels of augmented care, length of stay and death.
The ability of GPRD to conduct research across linked databases using this detailed clinical record data has
been proven in a population-based study on incidence, risk factors, clinical complications and drug
utilisation associated with seasonal influenza.[34]
GP clinical assessments and immediate management decisions are recorded on GPRD/LEPIS at time of
consultation. This data is downloaded nightly and collated for access by researchers on a weekly basis.
Data on hospital admission and death is typically entered on GPRD with in 48 hours of receipt of
notification. Recently Jick et al. (2011) described the ability of GPRD to provide near real-time analysis of
the epidemiology of pandemic influenza 2009.[35]
GPRD research group has gained ethical and National Information Governance Board (NIGB) approval to
provide anonymised data and other healthcare data linked via the patient’s NHS number, sex, date of birth
and post code.
GPs who contribute to the database use Vision® (In Practice Systems Ltd); a computer software package
designed by an established user-group of experienced GPs, to make contemporaneous records of their
routine consultations and enter study specific data in LEPIS; a linked application maintained by the GPRD
research team.
General Practitioners participating in the GPRD will be prompted on screen to record their assessment and
management of patients presenting with influenza like illness. A flag will appear during consultation
requesting the GP to complete their assessment on the LEPIS study website. This is the limit of any
variation from routine practise; which is to record assessment and key positive and negative rule-out
features in in free text fields in Vision®. It is important to note that GP are not expected to diverge from
their routine clinical assessment of patients and that GP management decisions are already routinely
entered in Vision®.
Hospitals are required to transmit discharge summaries to GPs within 48 hours or suffer financial penalties.
These contain high-level data: primary diagnosis, date of admission, date of discharge or death. This data
is manually input to Vision®, usually within 48 hours of receipt.
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Linked anonymised Vision® and LEPIS data is downloaded nightly in a silent background application to the
GPRD research group. Weekly extracts of the data are provided to the wider research community as
the GPRD.
Linkage to Hospital Episode Summary (HES) data is done by an external NHS group in a way that the GPRD
research team does not see any identifying details. HES data includes: method of admission, disease
coding (ICD-10), length of stay, level of augmented care, procedural coding (OPCS classification of
interventions and procedures, v4.6), cause of death as certified, prescribing and pharmaco-economics.
Levels of augmented care are defined by the Department of Health and Intensive Care Society Standard
(2009). These high-level data in HES have been mandated for return from all NHS hospitals in England for
all patients admitted to since April 2006 to support payment by results. HES data is linked to GPRD at
three monthly intervals and are provided to the wider research community.
The Office for National Statistics (ONS) collects information on causes of deaths from death certificates.
ONS data is linked to HES monthly and to GPRD every three months.
Notification of death is made by hospitals to GPs via standard operating procedures that ensure this data
is handled as a priority to prevent inappropriate communications and facilitate appropriate support to
bereaved relatives. Thus death as a status is entered on Vision® with little delay. Notice of ‘hospital
admission’ is normally available within 48 hours of admission. The primary outcome measures of hospital
admission and death are therefore available for use by GPRD following a nightly download. It is recognised
that there is typically a delay of 48 hours after discharge before high-level hospital admission data is
available from faxed hospital discharge letters. At the time of writing this proposal there is a 3-month
interval in linkage of GPRD to HES and ONS certified cause of death data.
Part of our work in phases 1 and 2 will be study feasibility, conducting necessary validation and if
necessary, initiate improved systems of data collection in the case of a pandemic.
Data management
The GPRD research group will undertake data collation and secure data warehousing in line with NIGB
requirements. The GPRD research group will provide direct access to the GPRD warehouse for the
statistician and epidemiologist. The researchers will have no access to patient identifiable data. All data
analysis and will be maintained on secured computer servers within the University of Nottingham and
University of Liverpool, only accessible to the research team and appropriately protected in accordance
with Caldicott principles.
Definition of influenza like illness
Influenza like illness (ILI) will be defined per the World Health Organization criteria: ‘any person with
sudden onset of fever (> 38 °C) and cough or sore throat in the absence of other diagnoses’. This closely
matches the Centres for Disease Control (CDC) USA definition used for community incidence studies:
‘fever or recent history of fever (≥ 37.8 °C) plus cough and or sore throat in the absence of a known cause
other than influenza’. This definition will include those people meeting the British Infection Society/British
Thoracic Society/Health Protection Agency/Department of Health (England) guidance criteria (2007):
‘presence or recent history of fever (T> 38 °C) plus new cough in the context of influenza circulating in the
community’. We have chosen not to adopt the Royal College of General Practitioners’ Syndromic
Surveillance System algorithm as it depends on self-reporting of muscle ache and or headache, which are
poorly reported by young children.
It is accepted that the definition of ILI may be revised in the event of a future pandemic, either on the basis
of on-going surveillance information or in the event of emergence of a novel pneumonic pathogen. This is
not a concern. This study’s aim is to establish automated processes capable of assessing and validating
community triage tools in near-real time, which can be applied regardless of any variations of the
case-defined entry criteria.
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Predictor variables
Clinical features of patients presenting with influenza like illness as recorded by GPs on LEPIS during their
routine consultation which include the criteria used by various triage tools:
1. Respiratory Rate (value)
2. Oxygen saturation (value)
3. Any sign of Severe Respiratory Distress (yes/no). Prompt ‘any of: lower chest wall indrawing, sternal
recession, grunting, noisy breathing when calm, use of accessory muscles, supra-clavicular recession,
tracheal tug, unable to complete sentences in one breath or feeling of suffocation’.
4. Respiratory Exhaustion (yes/no) or Apnoea reported (yes/no), apnoea defined as a ≥ 20-second pause
in breathing
5. Blood pressure (systolic and diastolic values)
6. Sternal Capillary Refill Time (normal/> 2 secs)
7. Severe dehydration (yes/no). Prompt: ‘any of: reduced skin turgor, sunken eyes or fontanelle’.
8. Adults only: New altered conscious level (yes/no). Prompt ‘any of: new confusion or disorientation in
person, place or time; AVCPU score <A; or ‘Mini (abbreviated) mental test score < 8’.
9. Children only: New altered conscious level (yes/no). Prompt ‘any of: new confusion or disorientation in
person, place or time; AVPU score < A; or Mini mental test score < 8/10’.
10. Strikingly agitated (yes/no)
11. New seizures (yes/no)
12. Floppy infant (yes/no)
13. Social isolation (yes/no). Prompt: ‘any of: lives alone; no fixed abode’.
14. Chronic disease (yes/no). Prompt: ‘any of respiratory, cardiac, renal, metabolic, immune suppressed or
sickle disease’.
15. Causing other clinical concern to their GP (yes/no). Prompt with ‘For example a rapidly progressive or
an unusually prolonged illness’ (yes/no).
Demographic data to be collected silently by background application
1. Practice location.
2. Socioeconomic data at lower super output level (index of multiple deprivations).
3. Ethnicity.
4. Sex.
5. Age.
6. In cases of death, Office of National Statistics cause of death.
Outcome measures
Primary outcome measures
1. Hospital admission within 24 hours of GP assessment.
2. Death within 30 days of GP assessment (all causes). Complications leading to death may occur after
some weeks (e.g. if prolonged admission to hospital). This outcome definition may miss cases that die
as a direct consequence of their illness after 30 days, but based on 2009/10 experiences these are
expected to be few.
Secondary outcome measures
1. Any need for augmented level of care during hospital admission i.e. level 2 – High Dependency and
level 3 – Intensive/Critical Care, accepting that there are minor differences between paediatric and adult
definitions of levels of care.
2. Length of hospital stay (stratified > 48 hours, ≥ 6 days and ≥ 12 days)
3. GP’s decision to refer for hospital admission.
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Statistical analysis
Separate analyses will be made for paediatric and adult patients and will use age appropriate triage tools
where available.
The datasets will be analysed using STATA statistical software.
Weekly cumulative analysis is planned using real-time data from GPRD followed by 3-monthly validation
using HES and ONS linked GPRD data. A rolling analysis is required because the virus, human behaviour,
and models of health care provision in the community may change in time. The analyses will be reset
in keeping with key policy changes in order to assess the impact of any changes. For example the
introduction of that automated National Pandemic Flu Service (NPFS) in July 2009 substantially reduced the
numbers and altered the case mix of people presenting to GPs.[31]
Univariate and multivariate analysis (using unconditional logistic regression) will be used to investigate the
association between triage criteria threshold values and primary outcomes (hospital admission and or
death). The threshold values of triage criteria will be refined by describing the receiver operator
characteristics of different thresholds of abnormality (e.g. respiratory rate > 30, > 35, > 40) to predict
patient outcomes.
It is likely that in the first couple of months of the pandemic, when there are fewer cases, the analyses will
be largely descriptive and focus on percentages and cross tabulations. However, as soon as it is feasible,
the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) will be
calculated for each of the triage tools using different triage tool score thresholds. An example of analysis
output is given in table 1. The discriminatory value of existing and refined triage tools will be compared
using logistic regression. The performance of different triage tools will be compared on their ability to
predict outcome using area under the Receiver Operating Characteristic curve (AUROC) comparisons.
An example of analysis output is given in figure 2.
Cumulative analysis will be reset between pandemic waves and appropriate comparisons made between
pandemic waves. Analyses can be reset if there is a substantial change to the model of pandemic influenza
health care provision such as introduction of an automated National Pandemic Influenza Service which
would be likely to alter the case mix presenting to GPs.
Risks/benefits to patients
For the individual patient there are no readily identifiable risks that result from the project. All data is
anonymised to allow analysis without compromising patient confidentiality. It is possible that participating
GPs will adapt their consultation practise to conduct clinical assessment in a structured format. This may
benefit patients.
Once the study processes are developed and piloted, the methods can be activated to determine the
appropriate management of other novel non-influenza severe acute respiratory pathogens, e.g.
SARS coronavirus.
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Risks/benefits to study
We have identified two system specific risks for the proposed study:
1. That despite prompts in the clinical software and other processes put in place to encourage data entry
by GPs (such as GPRD newsletters and emails), that GPs will not enter their assessment in LEPIS and
instead use other free-text fields in Vision®. To reduce this possibility, the software will be adapted to
flag a reminder if an ILI diagnostic code is entered in Vision® and the LEPIS study page has not
been completed.
2. It is accepted that there may be up to a week’s delay in availability of data from hospital discharge
faxes that is dependent upon manual input to Vision® by GPs clerks (e.g. length of stay). There is
potential for failure, reduced quality and increased delay of production of discharge faxes at some
hospitals due to local pandemic influenza pressures on staff and financial penalties may be lifted. This
will be mitigated by the very large size of the study recruiting from practices spread across the UK.
This risk is not expected to affect data return for the primary outcome (hospital admission within
24 hours of GP assessment) as this data is returned automatically or notice of death which is handled as
a priority to be communicated directly to GPs by clinical staff. Standard operating procedures are in
place ensure rapid disseminating of notice of death in primary care systems to prevent inappropriate
contacts and distress to bereaved relatives.
Consent
Patient consent is not required as all patient data is anonymised and no intervention is taking place.
Patients and parents of patients at participating practices have the opportunity to opt out of the GPRD
scheme at registration and any point thereafter. However after a patient has been assessed and their data
transmitted in an anonymised format there is not capability to redact that data. Anonymised patient
data in HES is subject to an NIGB section 251 approval for approved use without consent.
Ethics
GPRD research group has generic ethical approval for studies that only make use of anonymised data and
linked anonymised Hospital Episode Statistics. All studies require scientific approval from the GPRD
Independent Scientific Advisory Committee (ISAC). This study protocol will be submitted to ISAC for
review. In the event that ethical review is required by ISAC, a submission will be made to a Multi-Centre
Research Ethics Committee via the Integrated Research Application System.
The National Information Governance Board for Health and Social Care has authorised the Information
Centre for Health and Social Care to provide anonymised Hospital Episode Statistics as the official
statistical database on NHS hospital activity in England under a section 251 approval.
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Outputs from the study
In Phase one and two, progress reports to the oversight group will be made every three months, with a
final report being submitted at the end of phase two to NETSCC and Department of Health Pandemic
Influenza Planning Team.
Reports will detail:
l In Phase one
¢ GP involvement in developing data capture screens.
¢ User acceptability (GP) testing of data capture screens.
¢ Completeness of data from GPRD based on retrospective analysis using HES-linked GPRD data as a
gold standard for data completeness.
l In Phase two
¢ Weekly statistical analysis of cases of seasonal influenza to demonstrate capability of processes and
retrospective validation against HES data.
¢ An accrual graph of patients studied by week number plotted above the HPA Weekly National
Influenza Report of GP reported ILI consulting rates in the UK.
During phase three (pandemic), summary results of statistical analysis and recommendations regarding
the triage tools will be reported to the oversight committee on a fortnightly basis and shared with the
Pandemic Influenza Clinical Operation Clinical Subgroup (PICO) and the Scientific Advisory Group for
Emergencies (SAGE). The reporting cycle will be flexible and can be adapted to marry with the battle
rhythm of these key sources of advice to policy makers. The research team have a deep understanding of
the need to communicate their findings successfully.
Reports will detail:
l An accrual graph of patients studied by week number plotted above the HPA Weekly National
Influenza Report of GP reported ILI consulting rates in the UK.
l Results of statistical analysis detailing ROC, Sensitivity, Specificity, PPV, NPV for triage criteria and
AUROCs for triage tools against the primary outcomes: hospital admission, higher levels of care
(2 – HDU, 3 –ITU) and death.
l Recommendations regarding which criteria and tools to use in the event of surge.
In the post pandemic phase a final report will be produced and manuscripts prepared for publication.
Two of the investigators will present findings at an international conference.
Research governance
The University of Liverpool will act as sponsor for the study.
The proposed study will be undertaken in accordance with the University of Liverpool’s research
governance procedures.
Dr MG Semple (Liverpool) and Prof Jonathan Van-Tam (Nottingham) will be joint guarantors for analysis
and reports.
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Study oversight committee
A formal steering committee is impractical. A small independent oversight group has already been
convened which includes a research active principal in primary care with a particular interest in
identification of severe illness in children and a consultant in infectious diseases who is an expert in
translating evidence to policy and policy to practice. Both have already made recommendations to the
protocol that have been accepted.
Dr Anthony Harnden, Principle in General Practice and Director of Primary Care Research Network Clinical
(PCRN) Clinical Trials Unit Oxford. Dr Harnden is a member of PICO; appointed as an independent expert
clinical advisor in Primary Care. He has published on identifying factors that identify children with serious
infection in primary care, avoidable factors associated with chid deaths and the evidence base for
interventions delivered to children in primary care.
Dr Barbara Bannister, Consultant in Infectious Diseases, and Consultant Clinical Advisor to Department of
Health. Dr Bannister is a member of PICO; appointed as an expert clinical advisor in infectious diseases and
as a representative of the DH Pandemic Influenza Programme. Dr Bannister supported the development
and communication of operational guidance for medical professionals, including the mass use of antiviral
and antibiotic therapy, clinical management guidelines, NPFS algorithms, triage and hospital pathways.
A NIHR NETSCC monitor or representative will be invited to join the group.
In phase one and two the investigators plan to meet with the overseers at least at commencement and at
three monthly intervals.
In phase three, weekly reports will be presented to the overseers for ratification before being presented to
SAGE, PICO and policy makers in DH.
Timetable and milestones
01/04/2012 – 30/09/2010 Phase one (inter-pandemic – development / feasibility), duration six months
during a summer season: set-up and validation of processes, optimisation of the clinical record entry screen
in LEPIS, GP acceptability testing, completeness of data, validation of linkage between Vision®, LEPIS, HES
and GPRD, data-return format and development of data clean-up algorithms. Progress reports and meeting
at 3 and 6 months with overseers.
01/10/2012 – 31/03/2013 Phase two (inter-pandemic – pilot), duration six months in a winter season in
50 practices. Using data from cases of influenza like illness: test data-cleaning algorithms and the
automated weekly evaluation of performance of triage criteria and tools. Rehearsal of reporting procedures
and reporting rhythm to PICO and SAGE. Progress reports and meeting at 3 and 6 months with overseers.
A manuscript for publication will be produced at the completion of phase 2.
Phase three will be activated in the event of a pandemic, duration 12 months. We will run a weekly
cumulative analysis, allowing refinement of criteria and tools against the novel pandemic strain in readiness
for surge. Monthly summary reports to overseers during pandemic phase. When ready, refined and
validated tools will be presented to overseers, seeking approval to reporting to policy makers. Meeting at
least at 3, 6, and 9 months to overseers. A manuscript for publication will be produced in the post
pandemic period and before month 12.
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Expertise
The co-applicants at University of Liverpool (MGS) and Nottingham (JVT and PM) are experienced in
conducting pragmatic research during outbreaks and collaborated during the 2009 pandemic on the
FLU-CIN. Both groups have institutional support to reorganise work and time commitments in order to
conduct this research project as they did in 2009/10.
Dr MG (Calum) Semple (principal investigator) is a Senior Lecturer in Child Health at the University of
Liverpool and Consultant in Paediatric Respiratory Medicine at Alder Hey Children’s Hospital. His research
interests include investigating the clinical and immunological factors associated with severe respiratory viral
infections caused by human respiratory syncytial virus, human metapneumovirus and influenza virus. He
was seconded to the Department of Health Pandemic Influenza Programme as a clinical advisor from
2008 to 2010 and supported the development of clinical guidance, community triage tools and hospital
pathways in preparation for a future pandemic. At the onset of the 2009 A(H1N1) pandemic he joined the
Pandemic Influenza Clinical Operational Group (PICO) as an independent expert advisor and with Professor
Jonathan van Tam established the UK Pandemic Influenza Clinical Information Network (FLU-CIN).
Professor Jonathan Van Tam, University of Nottingham has a special interest in influenza: epidemiology;
transmission; vaccinology; and pandemic preparedness, which now spans more than 20 years. He is an
internationally renowned expert on influenza and senior editor of the textbook: Introduction to Pandemic
Influenza. He has been a consultant to the World Health Organization since 2004 and sits on the UK
Scientific Pandemic Influenza Committee (SPI), and its Pandemic Influenza Clinical and Operational Group
(PICO). He was a core member of the UK Scientific Advisory Group for Emergencies (SAGE) during the
2009-10 pandemic crisis and simultaneously led the national FLU-CIN surveillance project for hospitalised
pandemic flu cases; and two further ‘emergency’ pandemic research projects funded by NIHR. His unit is
an official WHO Collaborating Centre for pandemic influenza and research, a Faculty of Public Health
“national treasure” training location and an HPA Field Epidemiology training centre. He will provide this
specialist expertise to the study, particularly around study development and design and
policy-related analyses.
Dr Tjeerd-Pieter van Staa is head of GPRD Research. He is a physician with a MSc in Pharmaco-epidemiology
from McGill University and PhD from Utrecht University. He has more than 15 years of significant research
and industry experience in pharmaco-vigilance, epidemiology and pharmaco-economics. He has been the
European Qualified Person for Pharmacovigilance. His current research activities concern the combination
of prospective research methods with healthcare databases (including individual and cluster randomised
clinical trials within the database and pharmaco-genetic research). He has implemented collaborative
research of multiple health-data linkages, including cancer registries, MINAP, ALSPAC, air pollution and
bowel screening. Development of pharmaco-epidemiological methods, including multidatabase analyses
and visualisation and evaluation of data quality, is another research interest.
Dr Tim Williams is the GPRD research services manager. Tim Williams obtained a PhD from the University
of Leeds in 1995 before working within the Post Graduate Medical School at the University of Surrey as
a Research Fellow where he undertook technical and research aspects of UK primary care database
pharmacoepidemiology. In 2001 he moved to his current position, as an epidemiologist within the General
Practice Research Database division within the Medicines and Healthcare products Regulatory Agency. In
2003 he completed his MSc in Epidemiology from the London School of Hygiene and Tropical Medicine,
and he is also an Honorary Research Fellow with Brighton and Sussex Medical School.
Dr Puja Myles is associate professor of health protection at the University of Nottingham. Her PhD thesis
used a very large GP dataset to investigate risk factors for severe community acquired pneumonia. She
is the analyst on the FLU-CIN. She will provide the data processing, analytical and statistical expertise to
the study.
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Dr Jamie Kirkham is a lecturer in Medical Statistics within the Department of Biostatistics, University of
Liverpool. He has experience in statistical consultancy aimed specifically at improving the design and
analysis of research projects. He also has experience in developing and validating clinical assessment tools
(NIHR funded, Adverse Drug Reaction in Children project). He will provide methodological support to the
project and assist with the statistical analysis.
Service use input
The NIHR Primary Care Research Network (PCRN) Clinical Study Group have reviewed the study outline.
A principle in primary care (AH member of oversight committee) has reviewed to full protocol.
The GPRD research group and development practices include physicians and principles in General Practice
who have an appropriate vested interest in optimising the methods for data entry and developing
appropriate triage tools for us in the communities they care for.
Research staff requirements/justification of resources
The use of data derived from a very large data set is a complex undertaking and requires specific skills to
produce meaningful results. These include expertise in managing and manipulating large general practice
datasets, ‘cleaning’ the data, extracting the relevant information, statistical processing and interpreting the
findings appropriately. These need to be matched with relevant influenza clinical and public health skills,
including in primary and acute care, health protection and respiratory epidemiology. The research team has
therefore been drawn together to reflect these needs and includes expertise in handling large general
practice datasets and the relevant clinical skills.
Phases 1 and 2: PM will lead in drafting the application for submission to the GPRD ISAC. These forms
require detailed methodological description and would be difficult for someone without prior experience of
primary care database studies. She will oversee the development of data cleaning and analysis algorithms
and weekly report templates in preparation for Phase 3 as well as the validation of primary outcomes so
that definitions can be revised if necessary. She will provide supervision to the research assistant for
retrospective validation of real-time GPRD data using HES-linked GPRD data (which will be considered the
‘gold standard’ in terms of data completeness).
FT pre-doctoral research assistant: PM will be supported in this work by a full-time pre-doctoral research
assistant. In order to keep costs down, we have opted for a pre-doctoral RA but this will then require the
necessary input from PM as outlined previously.
Phase 3: PM: Ideally, data processing, analysis and production of weekly reports should be performed by a
full-time research assistant under PM’s supervision. However, it is our experience that, due to the
unpredictability of the timing of the pandemic and the need for an immediate start once the pandemic
begins, it will not be possible to go through usual recruitment procedures for employing an RA. Moreover,
even a very competent post-doctoral research assistant would need some level of training up in the project
specific role. In a pandemic situation there will be no scope for delays which is why PM will take full
responsibility of the data processing, analysis and production of weekly reports. This is usually a full-time
responsibility but we anticipate that the preparation carried out in Phases 1 and 2 will enable PM to carry
out these tasks at 60% whole time equivalent.
There are distinct differences in the time commitments required for the pre-pandemic phases (1 and 2) and
the pandemic phase 3 which will require increased activity. Research staff time has been adjusted
accordingly and to provide timely results to the overseers and policy makers.
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Staff and role
Time commitment (WTE) for FEC
Year 1 (phases 1 and 2), pre-pandemic Year 2 (phase 3), pandemic
MGS (PI and developer of triage tools) 10% 20%
PM (Very large database analyst) 20% 20%
Pre-doctoral Research Assistant 100% nil
JVT (Influenza Epidemiology) 3% 5%
JK (Methodology and statistical support) 3% 3%
Appendix 1 details costs for the technology solution planned by the research group, broken down by
phases of study and years of study.
Duration of the proposed project
1. Phase one (inter-pandemic – development and feasibility). Proposed start date 01.04.2012. Duration
six months during a summer season: set-up and validation of processes, optimisation of the clinical
record entry screen, GP acceptability testing, validation of linkage to hospital episode data, data-return
format and development of data clean-up algorithms.
2. Phase two (inter-pandemic – pilot). Proposed start date 01.10.2012. Duration six months in 10 to
20 practices during a winter season. Using data from people presenting with of influenza like illness:
test data-cleaning algorithms and the automated weekly evaluation of performance of triage criteria
and tools. The project will be mothballed at end of phase two.
3. Phase three will be activated in the event of a pandemic. The duration of a pandemic is hard to
estimate. Based on the 2009 event, time from detection of person-to-person spread in the UK to peak
activity was three months in the first wave with return to base line activity in a further one month. The
second wave had a broader base and longer tail lasting approximately 5 months. The modified GP
electronic record will be disseminated to all 629 GPRD practices by the routine update process. Weekly
analysis and outputs as described will require increased commitment from all investigators. Costing
phase three of the study for one year would allow checks on validity of tools to made between waves;
would allow for variations in health seeking behaviour and GP clinical practise between waves, plus a
three month wash up period for final analysis and reporting.
Ancillary costs
Weekly teleconferencing with all collaborators 1 hour, 5 lines, £40 per week= £4160.
Eight meetings (three monthly) of all collaborators £130 × 6 × 8= £6240.
Eight meetings (three monthly) of PI+ 1 (travel costs) with oversight committee (2). This will be conducted
jointly with a NETSCC Monitor from or nominated by NETSCC £130 × 4 × 8= £4160.
NETSCC will fund a maximum of two people to attend one international conference or one person to
attend two conferences (later is preferred option)= £4500.
Costs of two open-access publications (based on BMJ group rates at 01.09.2011) 2 × £1700= £3400.
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Appendix 1
Detailed cost breakdown for research group data acquisition, processing
and reporting
Activity
Phase 1,
6 months
Phase 2,
6 months
Phase 3 ,
2 months
Project administration practice liaisona
LEPIS software development / modification workb
Web based data acquisitionc
LEPIS running costsd
GPRD data processing modificationse
Develop data collation and cleaning algorithmsf
Development of automatic reporting scripts and embedding
analysis codeg
Scientific input (TVS and TW)h
System documentationi
GPRD data processing system modification and testingj
GPRD data costsk
Weekly download of data for study patientsl
Weekly execution of data extraction routinem
Produce and send weekly reportn
Subtotal
Year one, Pre-pandemic (phases 1 and 2)
Year two, Pandemic (phase 3)
Total GRPD costs
Notes
(a) Practice Liaison, User Acceptability Testing and management including roll out of required software
(b) Changes to LEPIS software
(c) Development and implementation Costs in P1 / P2
(d) P1 and P2 - Negligible running / P3 Software and IT support and maintenance costs
(e) Changes and further modifications to existing GPRD data processing systems
(f) Specific system for collating and cleaning raw collection data from General Practices
(g) P2 specific second phase action
(h) P1 and P2 - development; P3 There needs to be a provision for resolution of ‘data problems’ from HER data
(i) Documentation of system specification, design, testing and validation in line with Good Practise Requirement for Data
Handlers in eHealth Care Systems PICS
(j) P2 specific second phase action
(k) Waived by GPRD, typical cost £ per year
(l) P1 and P2 - Negligible costs; Cost for resources associated with extraction of data from master database.
(m) P1 and P2 - Negligible costs; On large P3 scale some provision should be available
(n) P1 design and development of report, P2 modifications to report, P3 Specific costs associated with large
volume distribution.
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